

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
**PATENT APPLICATION AND FEE TRANSMITTAL LETTER**

**LONDON, 3 DECEMBER 1999**  
**VIA DHL COURIER for HAND FILING**

Assistant Commissioner for Patents  
Customer Service Center  
Crystal Plaza 2  
Suite No. 1A031  
2011 S. Clark Place  
Arlington, VA 22202

Sir,

The following Utility Patent Application is enclosed for filing under 37 CFR 1.53(b):

Applicants:	Daniel E. AFAR, Rene S. HUBERT, Arthur B. RAITANO, Douglas C. SAFFRAN, Stephen C. MITCHELL
Executed on:	Inventors unavailable for execution at time of filing.
Title:	NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS AND USES THEREOF

Enclosed are the following:


- ☒ Specification - 56 pages.
- ☒ Drawings - 37 sheets.
- ☒ Small Entity Verification.
- ☒ Payment of the Filing Fee - Check in the amount of \$1754.00
- ☒ Return postcard.
- ☒ Duplicate copy of this Transmittal Letter
- ☐ Other -

FEE CALCULATION

BASIC FILING FEE [SMALL ENTITY]	\$ 380.00
TOTAL CLAIMS: 47 [27 in excess of 20 X \$9 - SMALL ENTITY]:	\$ 243.00
INDEPENDENT CLAIMS 32 [29 in excess of 3 X \$39 - SMALL ENTITY]:	\$1131.00
<b>TOTAL FILING FEES</b>	<b>\$1754.00</b>

Please direct all correspondence to the attention of: Law Office of Kenneth K. Sharples  
80 Fourth Street - P.O. Box 277  
Point Reyes Station, CA 94956  
Tel. 415-663-0323

Respectfully submitted,

  
Kenneth K. Sharples  
Reg. No. 35,355

jc675 U.S. PTO  
09/455486  
12/06/99

**VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN****Applicant:** Afar, Daniel et al.**Title:** NOVEL SERPENTINE TRANSMEMBRANE ANTIGEN EXPRESSED IN HUMAN  
CANCERS AND USES THEREOF**Application No.** Not Yet Assigned**Filed:** Concurrent Herewith

I hereby declare that I am:

- ☐ the owner of the small business concern identified below:  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

UroGenesys, Inc.  
1701 Colorado Avenue  
Santa Monica, CA

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both. I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☒ the specification filed herewith with title as listed above.  
☐ the application identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate verified statements averring to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). Each person, concern, or organization having any rights in the invention is listed below:

- ☒ no such person, concern, or organization exists.  
☐ each such person, concern, or organization is listed below.

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

**NAME OF PERSON SIGNING:**

Tracy M. Dolan


**TITLE OF PERSON IF OTHER THAN OWNER:**

Assistant Corporate Secretary

**ADDRESS OF PERSON SIGNING:**

UroGenesys, Inc.  
1701 Colorado Avenue  
Santa Monica, CA

SIGNATURE



DATE

December 2, 1999

**NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS**  
**EXPRESSED IN HUMAN CANCERS AND USES THEREOF**

**FIELD OF THE INVENTION**

- 5 The invention described herein relates to a family of novel genes and their encoded proteins and tumor antigens, termed STEAPs, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers, particularly including prostate cancer, colon cancer, bladder cancer, ovarian cancer and pancreatic cancer.

10 **BACKGROUND OF THE INVENTION**

- Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, cancer causes the death of well over a half-million people annually, with some 1.4 million new cases diagnosed per year. While deaths from heart disease have been declining significantly, those resulting from cancer generally are on the rise. In the early part of the next century, cancer is predicted to become the leading cause of death.

- Worldwide, several cancers stand out as the leading killers. In particular, carcinomas of the lung, prostate, breast, colon, pancreas, and ovary represent the primary causes of cancer death.
- 20 These and virtually all other carcinomas share a common lethal feature. With very few exceptions, metastatic disease from a carcinoma is fatal. Moreover, even for those cancer patients who initially survive their primary cancers, common experience has shown that their lives are dramatically altered. Many cancer patients experience strong anxieties driven by the awareness of the potential for recurrence or treatment failure. Many cancer patients experience physical debilitations following treatment, and many experience a recurrence.

- Generally speaking, the fundamental problem in the management of the deadliest cancers is the lack of effective and non-toxic systemic therapies. While molecular medicine promises to redefine the ways in which these cancers are managed, progress in this area has been slow despite intensive worldwide efforts to develop novel molecular diagnostics and therapeutics.
- 30 Fundamental to these efforts is the search for truly tumor-specific genes and proteins that could be used as diagnostic and prognostic markers and/or therapeutic targets or agents.

- As discussed below, the management of prostate cancer serves as a good example of the limited extent to which molecular biology has translated into real progress in the clinic. With limited exceptions, the situation is similar for the other major carcinomas mentioned above.
- 35

Worldwide, prostate cancer is the fourth most prevalent cancer in men. In North America and Northern Europe, it is by far the most common male cancer and is the second leading cause of cancer death in men. In the United States alone, well over 40,000 men die annually of this disease - second only to lung cancer. Despite the magnitude of these figures, there is still no effective treatment for metastatic prostate cancer. Surgical prostatectomy, radiation therapy, hormone ablation therapy, and chemotherapy continue to be the main treatment modalities. Unfortunately, these treatments are ineffective for many and are often associated with undesirable consequences.

- Most prostate cancers initially occur in the peripheral zone of the prostate gland, away from the urethra. Tumors within this zone may not produce any symptoms and, as a result, most men with early-stage prostate cancer will not present clinical symptoms of the disease until significant progression has occurred. Tumor progression into the transition zone of the prostate may lead to urethral obstruction, thus producing the first symptoms of the disease. However, these clinical symptoms are indistinguishable from the common non-malignant condition of benign prostatic hyperplasia (BPH).

- Early detection and diagnosis of prostate cancer currently relies on digital rectal examinations (DRE), prostate specific antigen (PSA) measurements, transrectal ultrasonography (TRUS), and transrectal needle biopsy (TRNB). At present, serum PSA measurement in combination with DRE represent the leading tool used to detect and diagnose prostate cancer. Both have major limitations which have fueled intensive research into finding better diagnostic markers of this disease.

- Accordingly, the lack of a prostate tumor marker that can accurately detect early-stage, localized tumors remains a significant limitation in the management of prostate cancer. A similar problem is the lack of an effective prognostic marker for determining which cancers are indolent and which ones are or will be aggressive. PSA, for example, cannot accurately discriminate between these alternatives.

- Although the serum PSA assay has been a very useful tool, its specificity and general utility is widely regarded as lacking in several important respects. For example, PSA is not a disease-specific marker, as elevated levels of PSA are detectable in a large percentage of patients with BPH and prostatitis (25-86%)(Gao et al., 1997, Prostate 31: 264-281), as well as in other nonmalignant disorders and in some normal men. Elevations in serum PSA of between 4 to 10 ng/ml are observed in BPH, and even higher values are observed in prostatitis, particularly acute prostatitis. BPH is an extremely common condition in men. Further confusing the situation is the fact that serum PSA elevations may be observed without any indication of disease from DRE,

and visa-versa. In addition, PSA diagnostics have sensitivities of only between 57-79% (Cupp & Osterling, 1993, Mayo Clin Proc 68:297-306), and thus miss identifying prostate cancer in a significant population of men with the disease. Moreover, it is now recognized that PSA is not prostate-specific (Gao et al., supra, for review). Various methods designed to improve the specificity of PSA-based detection have been described, such as measuring PSA density and the ratio of free vs. complexed PSA. However, none of these methodologies have been able to reproducibly distinguish benign from malignant prostate disease.

Similarly, there is no available marker that can predict the emergence of the typically fatal metastatic stage of prostate cancer. Diagnosis of the metastatic stage is presently achieved by open surgical or laparoscopic pelvic lymphadenectomy, whole body radionuclide scans, skeletal radiography, and/or bone lesion biopsy analysis. Clearly, better imaging and less invasive diagnostic methods would improve diagnostic accuracy, ease the burden such procedures place on patients, and open therapeutic options.

There are some known markers which are expressed predominantly in prostate, such as prostate specific membrane antigen (PSM), a hydrolase with 85% identity to a rat neuropeptidase (Carter et al., 1996, Proc. Natl. Acad. Sci. USA 93: 749; Bzdega et al., 1997, J. Neurochem. 69: 2270). However, the expression of PSM in small intestine and brain (Israeli et al., 1994, Cancer Res. 54: 1807), as well its potential role in neuropeptide catabolism in brain, raises concern of potential neurotoxicity with anti-PSM therapies. Preliminary results using an Indium-111 labeled, anti-PSM monoclonal antibody to image recurrent prostate cancer show some promise (Sodee et al., 1996, Clin Nuc Med 21: 759-766). More recently identified prostate cancer markers include PCTA-1 (Su et al., 1996, Proc. Natl. Acad. Sci. USA 93: 7252) and prostate stem cell antigen (PSCA) (Reiter et al., 1998, Proc. Natl. Acad. Sci. USA 95: 1735). PCTA-1, a novel galectin, is largely secreted into the media of expressing cells and may hold promise as a diagnostic serum marker for prostate cancer (Su et al., 1996). PSCA, a GPI-linked cell surface molecule, was cloned from LAPC-4 cDNA and is unique in that it is expressed primarily in basal cells of normal prostate tissue and in cancer epithelia (Reiter et al., 1998). Vaccines for prostate cancer are also being actively explored with a variety of antigens, including PSM and PSA.

### **SUMMARY OF THE INVENTION**

The present invention relates to a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed "STEAP" (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural

conservation among them but show no significant structural homology to any known human proteins.

The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C- termini, suggesting that it folds in a "serpentine" manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers. In particular, cell surface expression of STEAP-1 has been definitively confirmed in a variety of prostate and prostate cancer cells, bladder cancer cells and colon cancer cells. These characteristics indicate that STEAP-1 is a specific cell-surface tumor antigen expressed at high levels in prostate, bladder, colon, and other cancers.

A second member of the family, STEAP-2, is a 454 amino acid protein with a predicted molecular topology similar to that of STEAP-1. STEAP-2, like STEAP-1, is prostate-specific in normal human tissues and is also expressed in prostate cancer. Alignment of the STEAP-2 and STEAP-1 ORFs shows 54.9% identity over a 237 amino acid residue overlap, and the locations of the six putative transmembrane domains in STEAP-2 coincide with the locations of the transmembrane domains in STEAP-1 (FIG. 11A).

STEAP-3 and STEAP-4 are also described herein. These are also structurally related, and show unique expression profiles. In particular, STEAP-3 and STEAP-4 appear to show a different tissue restriction patterns. An amino acid sequence alignment of all four STEAPs is shown in FIG. 11A.

The invention provides polynucleotides corresponding or complementary to all or part of the STEAP genes, mRNAs, and/or coding sequences, preferably in isolated form, including polynucleotides encoding STEAP proteins and fragments thereof, DNA, RNA, DNA/RNA hybrid, and related molecules, polynucleotides or oligonucleotides complementary to the STEAP genes or mRNA sequences or parts thereof, and polynucleotides or oligonucleotides which hybridize to the STEAP genes, mRNAs, or to STEAP-encoding polynucleotides. Also provided are means for isolating cDNAs and the genes encoding STEAPs. Recombinant DNA molecules containing STEAP polynucleotides, cells transformed or transduced with such molecules, and host-vector systems for the expression of STEAP gene products are also provided. The invention further provides STEAP proteins and polypeptide fragments thereof. The invention further provides antibodies that bind to STEAP proteins and polypeptide fragments thereof, including polyclonal and monoclonal antibodies, murine and other mammalian antibodies, chimeric antibodies, humanized and fully human antibodies, and antibodies labeled with a detectable marker, and antibodies conjugated

to radionuclides, toxins or other therapeutic compositions. The invention further provides methods for detecting the presence of STEAP polynucleotides and proteins in various biological samples, as well as methods for identifying cells that express a STEAP. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, antibody, vaccine and small molecule therapy.

#### **BRIEF DESCRIPTION OF THE FIGURES**

FIG. 1. STEAP-1 structure. 1A: Nucleotide and deduced amino acid sequences of STEAP-1 (8P1B4) clone 10 cDNA (SEQ ID NOS. XX and XX, respectively). The start Methionine is indicated in bold at amino acid residue position 1 and six putative transmembrane domains are indicated in bold and are underlined. 1B: Schematic representation of STEAP-1 transmembrane orientation; amino acid residues bordering the predicted extracellular domains are indicated and correspond to the numbering scheme of FIG. 1A. 1C: G/C rich 5' non-coding sequence of the STEAP-1 gene as determined by overlapping sequences of clone 10 and clone 3.

FIG. 2. Predominant expression of STEAP-1 in prostate tissue. First strand cDNA was prepared from 16 normal tissues, the LAPC xenografts (4AD, 4AI and 9AD) and HeLa cells. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers derived from STEAP-1 (8P1D4) cDNA (FIG. 1A), shows predominant expression of STEAP-1 in normal prostate and the LAPC xenografts. The following primers were used to amplify STEAP-1:

8P1D4.1	5' ACTTTGTTGATGACCAGGATTGGA 3'	(SEQ ID NO: XX)
8P1D4.2	5' CAGAACTTCAGCACACACAGGAAC 3'	(SEQ ID NO: XX)

FIG. 3. Northern blot analyses of STEAP-1 expression in various normal human tissues and prostate cancer xenografts, showing predominant expression of STEAP-1 in prostate tissue. FIG. 3A: Two multiple tissue northern blots (Clontech) were probed with a full length STEAP cDNA clone 10 (FIG. 1A; SEQ ID NO: XX). Size standards in kilobases (kb) are indicated on the side. Each lane contains 2 µg of mRNA that was normalized by using a β-actin probe. FIG. 3B: Multiple tissue RNA dot blot (Clontech, Human Master Blot cat# 7770-1) probed with STEAP-1 cDNA clone 10 (FIG. 1A; SEQ ID NO: XX), showing approximately five-fold greater expression in prostate relative to other tissues with significant detectable expression.

FIG. 4. Nucleotide sequence of STEAP-1 GTH9 clone corresponding to the 4 kb message on northern blots (FIG. 3A). The sequence contains an intron of 2399 base pairs relative to the STEAP-1 clone 10 sequence of FIG. 1A; coding regions are nucleotides 96-857 and 3257- 3510 (indicated in bold). The start ATG is in bold and underlined, the STOP codon is in bold and underlined, and the intron-exon boundaries are underlined.

FIG. 5. Expression of STEAP-1 in prostate and multiple cancer cell lines and prostate cancer xenografts. Xenograft and cell line filters were prepared with 10  $\mu$ g of total RNA per lane. The blots were analyzed using the STEAP-1 clone 10 as probe. All RNA samples were normalized by ethidium bromide staining and subsequent analysis with a  $\beta$ -actin probe. FIG. 5A: Expression in various cancer cell lines and xenografts and prostate. Lanes as follows: (1) PrEC cells, (2) normal prostate tissue, (3) LAPC-4 AD xenograft, (4) LAPC-4 AI xenograft, (5) LAPC-9 AD xenograft, (6) LAPC-9 AI xenograft, (7) LNCaP cells, (8) PC-3 cells, (9) DU145 cells, (10) PANC-1 cells, (11) BxPC-3 cells, (12) HPAC cells, (13) Capan-1 cells, (14) CACO-2 cells, (15) LOVO cells, (16) T84 cells, (17) COLO-205 cells, (18) KCL-22 cells (acute lymphocytic leukemia, ALL), (19) HT1197 cells, (20) SCABER cells, (21) UM-UC-3 cells, (22) TCCSUP cells, (23) J82 cells, (24) 5637 cells, (25) RD-ES cells (Ewing sarcoma, EWS), (26) CAMA-1 cells, (27) DU4475 cells, (28) MCF-7 cells, (29) MDA-MB-435s cells, (30) NTERA-2 cells, (31) NCCIT cells, (32) TERA-1 cells, (33) TERA-2 cells, (34) A431 cells, (35) HeLa cells, (36) OV-1063 cells, (37) PA-1 cells, (38) SW 626 cells, (39) CAOV-3 cells. FIG. 5B: The expression of STEAP-1 in subcutaneously (sc) grown LAPC xenografts compared to the expression in LAPC-4 and LAPC-9 xenografts grown in the tibia (it) of mice.

FIG. 6. Western blot analysis of STEAP-1 protein expression in tissues and multiple cell lines. Western blots of cell lysates prepared from prostate cancer xenografts and cell lines were probed with a polyclonal anti-STEAP-1 antibody preparation (see Example XX for details). The samples contain 20  $\mu$ g of protein and were normalized with anti-Grb-2 probing of the Western blots.

FIG. 7. Cell surface biotinylation of STEAP-1. FIG. 7A: Cell surface biotinylation of 293T cells transfected with vector alone or with vector containing cDNA encoding 6His-tagged STEAP-1. Cell lysates were immunoprecipitated with specific antibodies, transferred to a membrane and probed with horseradish peroxidase-conjugated streptavidin. Lanes 1-4 and 6 correspond to immunoprecipitates from lysates prepared from STEAP-1 expressing 293T cells. Lanes 5 and 7 are immunoprecipitates from vector transfected cells. The immunoprecipitations were performed using the following antibodies: (1) sheep non-immune, (2) anti-Large T antigen, (3) anti-CD71 (transferrin receptor), (4) anti-His, (5) anti-His, (6) anti-STEAP-1, (7) anti-STEAP-1. FIG. 7B: Prostate cancer (LNCaP, PC-3, DU145), bladder cancer (UM-UC-3, TCCSUP) and colon cancer (LOVO, COLO) cell lines were either biotinylated (+) or not (-) prior to lysis. Western blots of streptavidin-gel purified proteins were probed with anti-STEAP-1 antibodies. Molecular weight markers are indicated in kilodaltons (kD).

FIG. 8. Immunohistochemical analysis of STEAP-1 expression using anti-STEAP-1 polyclonal antibody. Tissues were fixed in 10% formalin and embedded in paraffin. Tissue sections were



stained using anti-STEAP-1 polyclonal antibodies directed towards the N-terminal peptide. Samples include: (a) LNCaP cells probed in the presence of N-terminal STEAP-1 peptide 1, (b) LNCaP plus non specific peptide 2, (c) normal prostate tissue, (d) grade 3 prostate carcinoma, (e) grade 4 prostate carcinoma, (f) LAPC-9 AD xenograft, (g) normal bladder, (h) normal colon.

5 All images are at 400x magnification.

FIG. 9. Nucleotide and deduced amino acid sequences of STEAP-2 (98P4B6) clone GTD3 cDNA. The start methionine and Kozak sequence are indicated in bold, and the putative transmembrane domains are underlined in bold. The 5' UTR exhibits a high GC content of 72%

10

FIG. 10A. Nucleotide and deduced amino acid sequences of STEAP-3. Kozak region is bolded. FIG. 10B. Nucleotide sequences of dbest database entries corresponding to additional STEAP family members obtained by searching with the protein sequence of STEAP-1.

15 FIG. 11. Primary structural comparisons of STEAP family proteins:

FIG. 11A. Amino acid sequence alignment of STEAPs 1-4 using PIMA program (PIMA 1.4 program at Internet address: <<http://dot.imgen.bcm.tmc.edu:9331/multi-align/multi-align.html>>); transmembrane domains identified by the SOSUI program (available at Internet address <[http://www.tuat.ac.jp/~mitaku/adv\\_sosui/submit.html](http://www.tuat.ac.jp/~mitaku/adv_sosui/submit.html)>) are in bold. PIMA maximal linkage clustering results shown; identical residues shown in bold.

20

FIG. 11B. Amino acid sequence alignment of STEAP-1 (8P1D4 clone 10; SEQ ID NO: XX) and STEAP-2 (98P4B6 clone GTD3; SEQ ID NO: XX) sequences. The alignment was performed using the SIM alignment program of the Baylor College of Medicine Search Launcher Web site. Transmembrane domains are indicated in boldface. The results show a 54.9% identity in a 237 residues overlap (Score: 717.0; Gap frequency: 0.0%).

25

FIG. 11C. Amino acid sequence alignment of STEAP-1 and STEAP-3 (98P4B6 clone GTD3; SEQ ID NO: XX) sequences. Identical residues indicated with asterisks. SIM results: 40.9% identity in 264 residues overlap; Score: 625.0; Gap frequency: 0.0%.

30

FIG. 11D. Amino acid sequence alignment of STEAP-2 and STEAP-3 (98P4B6 clone GTD3; SEQ ID NO: XX) sequences. Identical residues indicated with asterisks. SIM results: 47.8% identity in 416 residues overlap; Score: 1075.0; Gap frequency: 0.2%.

35

FIG. 12. Expression of STEAP-3 mRNA in normal tissues by Northern blot (FIG. 12A) and RT-PCR (FIG. 12B). For RT-PCR analysis, first strand cDNA was prepared from 16 normal tissues.

Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to AI139607, shows predominant expression of AI139607 in placenta and prostate after 25 cycles of amplification. The following primers were used to amplify AI139607:

AI139607.1 5' TTAGGACAACTTGATCACCAGCA 3'

5 AI139607.2 5' TGTCCAGTCCAAACTGGGTTATTT 3'

FIG. 13. Predominant expression of STEAP-4/R80991 in liver. First strand cDNA was prepared from 16 normal tissues. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to R80991, shows predominant expression of R80991 in liver after 25 cycles of amplification. The following primers were used to amplify R80991:

R80991.1 5' AGGGAGTTCAGCTTCGTTCAAGTC 3'

R80991.2 5' GGTAGAACTTGTAGCGGCTCTCCT 3'

FIG. 14. Predominant expression of STEAP-2 (98P4B6) in prostate tissue. First strand cDNA was prepared from 8 normal tissues, the LAPC xenografts (4AD, 4AI and 9AD) and HeLa cells. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 98P4B6, shows predominant expression of 98P4B6 in normal prostate and the LAPC xenografts. The following primers were used to amplify STEAP II:

98P4B6.1 5' GACTGAGCTGGAAGTGAATTTGT 3'

20 98P4B6.2 5' TTTGAGGAGACTTCATCTCACTGG 3'

FIG. 15. Expression of the prostate-specific STEAP-2/98P4B6 gene in normal tissues and in prostate cancer xenografts determined by Northern blot analysis. Human normal tissue filters (A and B) were obtained from CLONTECH and contain 2 µg of mRNA per lane. Xenograft filter (C) was prepared with 10 µg of total RNA per lane. The blots were analyzed using the SSH derived 98P4B6 clone as probe. All RNA samples were normalized by ethidium bromide staining.

FIG. 16. Expression of STEAP-2 in prostate and select cancer cell lines as determined by Northern blot analysis. Xenograft and cell line filters were prepared with 10 µg total RNA per lane. The blots were analyzed using an SSH derived 98P4B6 clone as probe. All RNA samples were normalized by ethidium bromide staining.

FIG. 17. Chromosomal localization of STEAP family members. The chromosomal localizations of the STEAP genes described herein were determined using the GeneBridge4 radiation hybrid panel (Research Genetics, Huntsville AL). The mapping for STEAP-2 and AI139607 was performed using the Stanford G3 radiation hybrid panel (Research Genetics, Huntsville AL).

FIG. 18. Schematic representation of Intron-Exon boundaries within the ORF of human STEAP-1 gene. A total of 3 introns (i) and 4 exons (e) were identified.

FIG. 19. Zooblot southern analysis of STEAP-1 gene in various species. Genomic DNA was prepared from several different organisms including human, monkey, dog, mouse, chicken and Drosophila. Ten micrograms of each DNA sample was digested with EcoRI, blotted onto nitrocellulose and probed with a STEAP-1 probe. Size standards are indicated on the side in kilobases (kb).

FIG. 20. Southern blot analysis of mouse BAC with a STEAP-1 probe. DNA was prepared from human cells to isolate genomic DNA and from a mouse BAC clone (12P11) that contains the mouse STEAP gene. Each DNA sample was digested with EcoRI, blotted onto nitrocellulose and probed. Eight micrograms of genomic DNA was compared to 250 ng of mouse BAC DNA.

#### **DETAILED DESCRIPTION OF THE INVENTION**

Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd. edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted.

As used herein, the terms "advanced prostate cancer", "locally advanced prostate cancer", "advanced disease" and "locally advanced disease" mean prostate cancers which have extended through the prostate capsule, and are meant to include stage C disease under the American Urological Association (AUA) system, stage C1 - C2 disease under the Whitmore-Jewett system, and stage T3 - T4 and N+ disease under the TNM (tumor, node, metastasis) system. In general, surgery is not recommended for patients with locally advanced disease, and these patients have substantially less favorable outcomes compared to patients having clinically localized (organ-confined) prostate cancer. Locally advanced disease is clinically identified by palpable evidence of induration beyond the lateral border of the prostate, or asymmetry or induration above the

prostate base. Locally advanced prostate cancer is presently diagnosed pathologically following radical prostatectomy if the tumor invades or penetrates the prostatic capsule, extends into the surgical margin, or invades the seminal vesicles.

- 5 As used herein, the terms "metastatic prostate cancer" and "metastatic disease" mean prostate cancers which have spread to regional lymph nodes or to distant sites, and are meant to include stage D disease under the AUA system and stage TxNxM+ under the TNM system. As is the case with locally advanced prostate cancer, surgery is generally not indicated for patients with metastatic disease, and hormonal (androgen ablation) therapy is the preferred treatment
- 10 modality. Patients with metastatic prostate cancer eventually develop an androgen-refractory state within 12 to 18 months of treatment initiation, and approximately half of these patients die within 6 months thereafter. The most common site for prostate cancer metastasis is bone. Prostate cancer bone metastases are, on balance, characteristically osteoblastic rather than osteolytic (i.e., resulting in net bone formation). Bone metastases are found most frequently in
- 15 the spine, followed by the femur, pelvis, rib cage, skull and humerus. Other common sites for metastasis include lymph nodes, lung, liver and brain. Metastatic prostate cancer is typically diagnosed by open or laparoscopic pelvic lymphadenectomy, whole body radionuclide scans, skeletal radiography, and/or bone lesion biopsy.
- 20 As used herein, the term "polynucleotide" means a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA.

- As used herein, the term "polypeptide" means a polymer of at least 8 amino acids. Throughout
- 25 the specification, standard three letter or single letter designations for amino acids are used.

- As used herein, the terms "hybridize", "hybridizing", "hybridizes" and the like, used in the context of polynucleotides, are meant to refer to conventional hybridization conditions, preferably such as hybridization in 50% formamide/6XSSC/0.1% SDS/100 µg/ml ssDNA, in which temperatures for
- 30 hybridization are above 37 degrees C and temperatures for washing in 0.1XSSC/0.1% SDS are above 55 degrees C, and most preferably to stringent hybridization conditions.

- In the context of amino acid sequence comparisons, the term "identity" is used to express the percentage of amino acid residues at the same relative position which are the same. Also in this
- 35 context, the term "homology" is used to express the percentage of amino acid residues at the same relative positions which are either identical or are similar, using the conserved amino acid criteria of BLAST analysis, as is generally understood in the art. Further details regarding amino acid substitutions, which are considered conservative under such criteria, are provided below.

Additional definitions are provided throughout the subsections which follow.

### **MOLECULAR AND BIOCHEMICAL FEATURES OF THE STEAPs**

- 5 The invention relates to a novel family of proteins, termed STEAPs. Four STEAPs are specifically described herein by way of structural, molecular and biochemical features. As is further described in the Examples which follow, the STEAPs have been characterized in a variety of ways. For example, analyses of nucleotide coding and amino acid sequences were conducted in order to identify conserved structural elements within the STEAP family. Extensive RT-PCR and
- 10 Northern blot analyses of STEAP mRNA expression were conducted in order to establish the range of normal and cancerous tissues expressing the various STEAP messages. Western blot, immunohistochemical and flow cytometric analyses of STEAP protein expression were conducted to determine protein expression profiles, cell surface localization and gross molecular topology of STEAP.
- 15 The prototype member of the STEAP family, STEAP-1, is a six-transmembrane cell surface protein of 339 amino acids with no identifiable homology to any known human protein. The cDNA nucleotide and deduced amino acid sequences of human STEAP-1 are shown in FIG. 1A. A gross topological schematic of the STEAP-1 protein integrated within the cell membrane is shown
- 20 in FIG. 1B. STEAP-1 expression is predominantly prostate-specific in normal tissues. Specifically, extensive analysis of STEAP-1 mRNA and protein expression in normal human tissues shows that STEAP-1 protein is predominantly expressed in prostate and, to a far smaller degree, in bladder. STEAP-1 mRNA is also relatively prostate specific, with only very low level expression detected in a few other normal tissues. In cancer, STEAP-1 mRNA and protein is consistently expressed at
- 25 high levels in prostate cancer (including androgen-dependent and androgen-independent tumors) and during all stages of the disease. STEAP-1 is also expressed in other cancers. Specifically, STEAP-1 mRNA is expressed at very high levels in bladder, colon, pancreatic, and ovarian cancer (as well as other cancers). In addition, cell surface expression of STEAP-1 protein has been established in prostate, bladder and colon cancers. Therefore, STEAP-1 has all of the hallmark
- 30 characteristics of an excellent therapeutic target for the treatment of certain cancers, including particularly prostate, colon and bladder carcinomas.

- A second member of the family, STEAP-2, is a 454 amino acid protein encoded by a distinct gene and having a predicted molecular topology similar to that of STEAP-1. The cDNA nucleotide and deduced amino acid sequences of STEAP-2 are shown in FIG. 9. Amino acid alignment of the
- 35 STEAP-1 and STEAP-2 sequences show a high degree of structural conservation (54.9% identity over a 237 amino acid residue overlap, and the locations of the six putative transmembrane domains in STEAP-1 and STEAP-2 coincide (FIGS. 11A, 11B). Structural homology between

these STEAP-1 and STEAP-2 is highest in the regions spanned by the first putative extracellular loop to the fifth transmembrane domain. However, some significant structural differences between STEAP-1 and STEAP-2 are apparent. For example, STEAP-2 exhibits a 205 a.a. long intracellular N-terminus (compared to 69 a.a. in STEAP-1) and a short 4 a.a. intracellular C-terminus (compared to 26 a.a. in STEAP-1). In addition, both the STEAP-1 and STEAP-2 genes are located on chromosome 7, but on different arms. These differences could imply significant differences in function and/or interaction with intracellular signaling pathways.

STEAP-2 is expressed only in normal prostate among human tissues tested (FIGS. 14 and 15) and is also expressed in prostate cancer (FIG. 15), and thus shows some similarity in expression profile to STEAP-1. However, STEAP-2 exhibits a different mRNA expression profile relative to STEAP-1 in prostate cancer samples (compare FIGS. 3 and 15) and in other non-prostate cancers tested (compare FIGS. 5 and 16). These differences in the expression profiles of STEAP-1 and STEAP-2 suggest that they are differentially regulated.

STEAP-3 and STEAP-4 appear to be closely related to both STEAP-1 and STEAP-2 on a structural level, and both appear to be transmembrane proteins as well. STEAP-3 is more related to STEAP-2 (47.8% identity) than to STEAP-1 (40.9% identity). STEAP-3 and STEAP-4 show unique expression profiles. STEAP-3, for example, appears to have an expression pattern which is predominantly restricted to placenta and, to a smaller degree, expression is seen in prostate but not in other normal tissues tested. STEAP-4 seems to be expressed predominantly in liver by RT-PCR analysis. Neither STEAP-3 nor STEAP-4 appear to be expressed in prostate cancer xenografts which exhibit high level STEAP-1 and STEAP-2 expression.

Three of the four STEAPs described herein map to human chromosome 7 (STEAP-1, -2 and 3). Interestingly, STEAP-1 maps within 7p22 (7p22.3), a large region of allelic gain reported for both primary and recurrent prostate cancers (Visakorpi et al., 1995 Cancer Res. 55: 342, Nupponen et al., 1998 American J. Pathol. 153: 141), suggesting that up-regulation of STEAP-1 in cancer might include genomic mechanisms. In addition, both STEAP-2 and STEAP-3 locate to chromosome 7q21, suggesting that these two genes arose by gene duplication.

The function of the STEAPs are not known. Other cell surface molecules that contain six transmembrane domains include ion channels (Dolly and Parcej, 1996 J Bioenerg Biomembr 28:231) and water channels or aquaporins (Reizer et al., 1993 Crit Rev Biochem Mol Biol 28:235). Structural studies show that both types of molecules assemble into tetrameric complexes to form functional channels (Christie, 1995, Clin Exp Pharmacol Physiol 22:944, Walz et al., 1997 Nature 387:624, Cheng et al., 1997 Nature 387:627). Immunohistochemical staining of STEAP-1 in the prostate gland seems to be concentrated at the cell-cell boundaries, with less

staining detected at the luminal side. This may suggest a role for STEAP-1 in tight-junctions, gap-junctions or cell communication and adhesion. In order to test these possibilities, xenopus oocytes (or other cells) expressing STEAP may be analyzed using voltage-clamp and patch-clamp experiments to determine if STEAP functions as an ion-channel. Oocyte cell volume may also be measured to determine if STEAP exhibits water channel properties. If STEAPs function as channel or gap-junction proteins, they may serve as excellent targets for inhibition using, for example, antibodies, small molecules, and polynucleotides capable of inhibiting expression or function. The restricted expression pattern in normal tissue, and the high levels of expression in cancer tissue suggest that interfering with STEAP function may selectively kill cancer cells.

Since the STEAP gene family is predominantly expressed in epithelial tissue, it seems possible that the STEAP proteins function as ion channels, transport proteins or gap-junction proteins in epithelial cell function. Ion channels have been implicated in proliferation and invasiveness of prostate cancer cells (Lalani et al., 1997, Cancer Metastasis Rev 16:29). Both rat and human prostate cancer cells contain sub-population of cells with higher and lower expression levels of sodium channels. Higher levels of sodium channel expression correlate with more aggressive invasiveness in vitro (Smith et al., 1998, FEBS Lett. 423:19). Similarly, it has been shown that a specific blockade of sodium channels inhibits the invasiveness of PC-3 cells in vitro (Laniado et al., 1997, Am. J. Pathol. 150:1213), while specific inhibition of potassium channels in LNCaP cells inhibited cell proliferation (Skryma et al., 1997, Prostate 33:112). These reports suggest a role for ion channels in prostate cancer and also demonstrate that small molecules that inhibit ion channel function may interfere with prostate cancer proliferation.

#### **STEAP POLYNUCLEOTIDES**

One aspect of the invention provides polynucleotides corresponding or complementary to all or part of a STEAP gene, mRNA, and/or coding sequence, preferably in isolated form, including polynucleotides encoding a STEAP protein and fragments thereof, DNA, RNA, DNA/RNA hybrid, and related molecules, polynucleotides or oligonucleotides complementary to a STEAP gene or mRNA sequence or a part thereof, and polynucleotides or oligonucleotides which hybridize to a STEAP gene, mRNA, or to a STEAP-encoding polynucleotide (collectively, "STEAP polynucleotides"). As used herein, STEAP genes and proteins are meant to include the STEAP-1, STEAP-2 and STEAP-3 genes and proteins, and the gene and protein corresponding to GeneBank Accession number R80991 (STEAP-4), and the genes and proteins corresponding to other STEAP proteins and structurally similar variants of the foregoing. Such other STEAP proteins and variants will generally have coding sequences which are highly homologous to the STEAP coding sequences provided herein, and preferably will share at least about 50% amino acid identity and

at least about 60% amino acid homology (using BLAST criteria), more preferably sharing 70% or greater homology (using BLAST criteria).

5 The STEAP family member gene sequences described herein encode STEAP proteins sharing unique highly conserved amino acid sequence domains which distinguish them from other proteins. Proteins which include one or more of these unique highly conserved domains may be related to the STEAP family members or may represent new STEAP proteins. Referring to FIG. 11A, which is an amino acid sequence alignment of the full STEAP-1, STEAP-2, and STEAP-3 protein sequences as well as the partial STEAP-4 sequence, it is clear that the STEAPs are closely  
10 related at the structural level. Referring to FIG. 11B, which is an amino acid sequence alignment of the full STEAP-1 and STEAP-2 protein sequences, close structural conservation is apparent, particularly in the predicted transmembrane domains. The STEAP-1 and STEAP-2 sequences share 54.9% identity over a 237 amino acid overlap. Additional amino acid sequence alignments between the STEAPs are shown in FIGS. 11C and 11D. These alignments show that  
15 STEAP-1 and STEAP-3 are 40.9% identical over a 264 amino acid region, while STEAP-2 and STEAP-3 are 47.8% identical over a 416 amino acid region.

A STEAP polynucleotide may comprise a polynucleotide having the nucleotide sequence of human STEAP-1 as shown in FIG. 1A, the nucleotide sequence of human STEAP-2 as shown in FIG. 9,  
20 the nucleotide sequence of human STEAP-3 as shown in FIG. 10A, or the nucleotide sequence of STEAP-4 as shown in FIG. 10B, or a sequence complementary thereto, or a polynucleotide fragment of any of the foregoing. Another embodiment comprises a polynucleotide which encodes the human STEAP-1, STEAP-2, STEAP-3 or STEAP-4 protein amino acid sequences, a sequence complementary thereto, or a polynucleotide fragment of any of the foregoing. Another  
25 embodiment comprises a polynucleotide which is capable of hybridizing under stringent hybridization conditions to the human STEAP-1 cDNA shown in FIG. 1A, the human STEAP-2 cDNA shown in FIG. 9, the human STEAP-3 cDNA shown in FIG. 10A, or the STEAP-4 as shown in FIG. 10B, or to a polynucleotide fragment thereof.

30 Specifically contemplated are genomic DNA, cDNAs, ribozymes, and antisense molecules, as well as nucleic acid molecules based on an alternative backbone or including alternative bases, whether derived from natural sources or synthesized. For example, antisense molecules can be RNAs or other molecules, including peptide nucleic acids (PNAs) or non-nucleic acid molecules such as phosphorothioate derivatives, that specifically bind DNA or RNA in a base pair-dependent  
35 manner. The skilled person can readily obtain these classes of nucleic acid molecules using the STEAP polynucleotides and polynucleotide sequences disclosed herein.



Further specific embodiments of this aspect of the invention include primers and primer pairs, which allow the specific amplification of the polynucleotides of the invention or of any specific parts thereof, and probes that selectively or specifically hybridize to nucleic acid molecules of the invention or to any part thereof. Probes may be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator or enzyme. Such probes and primers can be used to detect the presence of a STEAP polynucleotide in a sample and as a means for detecting a cell expressing a STEAP protein. Examples of such probes include polynucleotides comprising all or part of the human STEAP-1, STEAP-2 and STEAP-3 cDNA sequences shown in FIGS. 1A, 9 and 10A, respectively. Examples of primer pairs capable of specifically amplifying STEAP mRNAs are also described in the Examples which follow. As will be understood by the skilled person, a great many different primers and probes may be prepared based on the sequences provided in herein and used effectively to amplify and/or detect a STEAP mRNA or an mRNA encoding a particular STEAP family member.

As used herein, a polynucleotide is said to be "isolated" when it is substantially separated from contaminant polynucleotides which correspond or are complementary to genes other than the STEAP gene from which the polynucleotide is derived or which encode polypeptides other than the corresponding STEAP gene product or fragment thereof. The skilled person can readily employ nucleic acid isolation procedures to obtain an isolated STEAP polynucleotides.

The STEAP polynucleotides of the invention are useful for a variety of purposes, including but not limited to their use as probes and primers for the amplification and/or detection of the STEAP gene(s), mRNA(s), or fragments thereof; as reagents for the diagnosis and/or prognosis of prostate cancer and other cancers; as coding sequences capable of directing the expression of STEAP polypeptides; as tools for modulating or inhibiting the expression of the STEAP gene(s) and/or translation of the STEAP transcript(s); and as therapeutic agents.

#### **METHODS FOR ISOLATING STEAP-ENCODING NUCLEIC ACID MOLECULES**

The STEAP cDNA sequences described herein enable the isolation of other polynucleotides encoding STEAP gene product(s), as well as the isolation of polynucleotides encoding STEAP gene product homologues, alternatively spliced isoforms, allelic variants, and mutant forms of the STEAP gene product. Various molecular cloning methods that can be employed to isolate full length cDNAs encoding a STEAP gene are well known (See, for example, Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, 2d edition., Cold Spring Harbor Press, New York, 1989; Current Protocols in Molecular Biology. Ausubel et al., Eds., Wiley and Sons, 1995). For example, lambda phage cloning methodologies may be conveniently employed, using commercially available cloning systems (e.g., Lambda ZAP Express, Stratagene). Phage clones containing STEAP gene cDNAs may

be identified by probing with a labeled STEAP cDNA or a fragment thereof. For example, in one embodiment, the STEAP-1 cDNA (FIG. 1A) or a portion thereof can be synthesized and used as a probe to retrieve overlapping and full length cDNAs corresponding to a STEAP gene. Similarly, the STEAP-2 and STEAP-3 cDNA sequences may be employed. A STEAP gene may be isolated by screening genomic DNA libraries, bacterial artificial chromosome libraries (BACs), yeast artificial chromosome libraries (YACs), and the like, with STEAP DNA probes or primers.

#### **RECOMBINANT DNA MOLECULES AND HOST-VECTOR SYSTEMS**

The invention also provides recombinant DNA or RNA molecules containing a STEAP polynucleotide, including but not limited to phages, plasmids, phagemids, cosmids, YACs, BACs, as well as various viral and non-viral vectors well known in the art, and cells transformed or transfected with such recombinant DNA or RNA molecules. As used herein, a recombinant DNA or RNA molecule is a DNA or RNA molecule that has been subjected to molecular manipulation *in vitro*. Methods for generating such molecules are well known (see, for example, Sambrook et al, 1989, supra).

The invention further provides a host-vector system comprising a recombinant DNA molecule containing a STEAP polynucleotide within a suitable prokaryotic or eukaryotic host cell. Examples of suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell or an insect cell (e.g., a baculovirus-infectible cell such as an Sf9 cell). Examples of suitable mammalian cells include various prostate cancer cell lines such LnCaP, PC-3, DU145, LAPC-4, TsuPr1, other transfectable or transducible prostate cancer cell lines, as well as a number of mammalian cells routinely used for the expression of recombinant proteins (e.g., COS, CHO, 293, 293T cells). More particularly, a polynucleotide comprising the coding sequence of a STEAP may be used to generate STEAP proteins or fragments thereof using any number of host-vector systems routinely used and widely known in the art.

A wide range of host-vector systems suitable for the expression of STEAP proteins or fragments thereof are available, see for example, Sambrook et al., 1989, supra; Current Protocols in Molecular Biology, 1995, supra). Preferred vectors for mammalian expression include but are not limited to pcDNA 3.1 myc-His-tag (Invitrogen) and the retroviral vector pSR $\alpha$ tkneo (Muller et al., 1991, MCB 11:1785). Using these expression vectors, STEAP may be preferably expressed in several prostate cancer and non-prostate cell lines, including for example 293, 293T, rat-1, 3T3, PC-3, LNCaP and TsuPr1. The host-vector systems of the invention are useful for the production of a STEAP protein or fragment thereof. Such host-vector systems may be employed to study the functional properties of STEAP and STEAP mutations.

Proteins encoded by the STEAP genes, or by fragments thereof, will have a variety of uses, including but not limited to generating antibodies and in methods for identifying ligands and other

agents and cellular constituents that bind to a STEAP gene product. Antibodies raised against a STEAP protein or fragment thereof may be useful in diagnostic and prognostic assays, imaging methodologies (including, particularly, cancer imaging), and therapeutic methods in the management of human cancers characterized by expression of a STEAP protein, such as prostate, colon, breast, cervical and bladder carcinomas, ovarian cancers, testicular cancers and pancreatic cancers. Various immunological assays useful for the detection of STEAP proteins are contemplated, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), immunocytochemical methods, and the like. Such antibodies may be labeled and used as immunological imaging reagents capable of detecting prostate cells (e.g., in radioscintigraphic imaging methods). STEAP proteins may also be particularly useful in generating cancer vaccines, as further described below.

### **STEAP PROTEINS**

Another aspect of the present invention provides various STEAP proteins and polypeptide fragments thereof. As used herein, a STEAP protein refers to a protein that has or includes the amino acid sequence of human STEAP-1 as provided in FIG. 1A, human STEAP-2 as provided in FIG. 9, human STEAP-3 as provided in FIG. 10A, the amino acid sequence of other mammalian STEAP homologues (e.g., STEAP-4) and variants, as well as allelic variants and conservative substitution mutants of these proteins that have STEAP biological activity.

The STEAP proteins of the invention include those specifically identified herein, as well as allelic variants, conservative substitution variants and homologs that can be isolated/generated and characterized without undue experimentation following the methods outlined below. Fusion proteins which combine parts of different STEAP proteins or fragments thereof, as well as fusion proteins of a STEAP protein and a heterologous polypeptide are also included. Such STEAP proteins will be collectively referred to as the STEAP proteins, the proteins of the invention, or STEAP. As used herein, the term "STEAP polypeptide" refers to a polypeptide fragment or a STEAP protein of at least 8 amino acids, preferably at least 10 amino acids.

A specific embodiment of a STEAP protein comprises a polypeptide having the amino acid sequence of human STEAP-1 as shown in FIG. 1A. Another embodiment of a STEAP protein comprises a polypeptide containing the STEAP-2 amino acid sequence as shown in FIG. 9. Another embodiment comprises a polypeptide containing the STEAP-3 amino acid sequence of shown in FIG. 10A. Yet another embodiment comprises a polypeptide containing the partial STEAP-4 amino acid sequence of shown in FIG. 11A.

In general, naturally occurring allelic variants of individual human STEAPs will share a high degree of structural identity and homology (e.g., 90% or more identity). Typically, allelic variants of the STEAP proteins will contain conservative amino acid substitutions within the STEAP sequences described herein or will contain a substitution of an amino acid from a corresponding position in a STEAP homologue. One class of STEAP allelic variants will be proteins that share a high degree of homology with at least a small region of a particular STEAP amino acid sequence, but will further contain a radical departure from the sequence, such as a non-conservative substitution, truncation, insertion or frame shift. Such alleles may represent mutant STEAP proteins that typically do not perform the same biological functions or do not have all of the biological characteristics.

10

Conservative amino acid substitutions can frequently be made in a protein without altering either the conformation or the function of the protein. Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered "conservative" in particular environments.

25 STEAP proteins may be embodied in many forms, preferably in isolated form. As used herein, a protein is said to be "isolated" when physical, mechanical or chemical methods are employed to remove the STEAP protein from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated STEAP protein. A purified STEAP protein molecule will be substantially free of other proteins or molecules which impair the binding of STEAP to antibody or other ligand. The nature and degree of isolation and purification will depend on the intended use. Embodiments of a STEAP protein include a purified STEAP protein and a functional, soluble STEAP protein. In one form, such functional, soluble STEAP proteins or fragments thereof retain the ability to bind antibody or other ligand.

35

The invention also provides STEAP polypeptides comprising biologically active fragments of the STEAP amino acid sequence, such as a polypeptide corresponding to part of the amino acid sequences for STEAP-1 as shown in FIG. 1A, STEAP-2 as shown in FIG. 9, STEAP-3 as shown in

FIG. 10A, or STEAP-4 as shown in FIG. 11A. Such polypeptides of the invention exhibit properties of a STEAP protein, such as the ability to elicit the generation of antibodies which specifically bind an epitope associated with a STEAP protein. Polypeptides comprising amino acid sequences which are unique to a particular STEAP protein (relative to other STEAP proteins) may be used to generate antibodies which will specifically react with that particular STEAP protein. For example, referring to the amino acid alignment of the STEAP structures shown in FIGS. 11A-D, the skilled artisan will readily appreciate that each molecule contains stretches of sequence unique to its structure. These unique stretches can be used to generate antibodies specific to a particular STEAP. Similarly, regions of conserved sequence may be used to generate antibodies that may bind to multiple STEAPs.

STEAP polypeptides can be generated using standard peptide synthesis technology or using chemical cleavage methods well known in the art based on the amino acid sequences of the human STEAP proteins disclosed herein. Alternatively, recombinant methods can be used to generate nucleic acid molecules that encode a polypeptide fragment of a STEAP protein. In this regard, the STEAP-encoding nucleic acid molecules described herein provide means for generating defined polypeptide fragments of STEAP proteins. Such STEAP polypeptides or peptides are particularly useful for generating and characterizing domain specific antibodies (e.g., antibodies recognizing an extracellular or intracellular epitope of a STEAP protein), generating STEAP family member specific antibodies (e.g., anti-STEAP-1, anti-STEAP 2 antibodies), identifying agents or cellular factors that bind to a particular STEAP or STEAP domain, and in various therapeutic contexts, including but not limited to cancer vaccines. STEAP polypeptides containing particularly interesting structures can be predicted and/or identified using various analytical techniques well known in the art, including, for example, the methods of Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis, or on the basis of immunogenicity. Fragments containing such structures are particularly useful in generating subunit specific anti-STEAP antibodies or in identifying cellular factors that bind to STEAP.

### **STEAP ANTIBODIES**

Another aspect of the invention provides antibodies that bind to STEAP proteins and polypeptides. The most preferred antibodies will specifically bind to a STEAP protein and will not bind (or will bind weakly) to non-STEAP proteins and polypeptides. Anti-STEAP antibodies that are particularly contemplated include monoclonal and polyclonal antibodies as well as fragments containing the antigen binding domain and/or one or more complementarity determining regions of these antibodies. As used herein, an antibody fragment is defined as at least a portion of the variable region of the immunoglobulin molecule which binds to its target, i.e., the antigen binding region.

For some applications, it may be desirable to generate antibodies which specifically react with a particular STEAP protein and/or an epitope within a particular structural domain. For example, preferred antibodies useful for cancer therapy and diagnostic imaging purposes are those which react with an epitope in an extracellular region of the STEAP protein as expressed in cancer cells.

5 Such antibodies may be generated by using the STEAP proteins described herein, or using peptides derived from predicted extracellular domains thereof, as an immunogen. In this regard, with reference to the STEAP-1 protein topological schematic shown in FIG 1B, regions in the extracellular loops between the indicated transmembrane domains may be selected as used to design appropriate immunogens for raising extracellular-specific antibodies.

10

STEAP antibodies of the invention may be particularly useful in prostate cancer therapeutic strategies, diagnostic and prognostic assays, and imaging methodologies. The invention provides various immunological assays useful for the detection and quantification of STEAP and mutant STEAP proteins and polypeptides. Such assays generally comprise one or more STEAP antibodies  
15 capable of recognizing and binding a STEAP or mutant STEAP protein, as appropriate, and may be performed within various immunological assay formats well known in the art, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), and the like. In addition, immunological imaging methods capable of detecting prostate cancer are also provided by the invention, including but  
20 limited to radioscintigraphic imaging methods using labeled STEAP antibodies. Such assays may be clinically useful in the detection, monitoring, and prognosis of prostate cancer, particularly advanced prostate cancer.

The invention also provides various immunological assays useful for the detection and quantification  
25 of STEAP and mutant STEAP proteins and polypeptides. Such assays generally comprise one or more STEAP antibodies capable of recognizing and binding a STEAP or mutant STEAP protein, as appropriate, and may be performed within various immunological assay formats well known in the art, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), and the like. In addition,  
30 immunological imaging methods capable of detecting prostate cancer and other cancers expressing STEAP (e.g., breast cancer) are also provided by the invention, including but limited to radioscintigraphic imaging methods using labeled STEAP antibodies. Such assays may be clinically useful in the detection, monitoring, and prognosis of STEAP expressing cancers such as prostate cancer.

35

STEAP antibodies may also be used in methods for purifying STEAP and mutant STEAP proteins and polypeptides and for isolating STEAP homologues and related molecules. For example, in one embodiment, the method of purifying a STEAP protein comprises incubating a STEAP antibody,

which has been coupled to a solid matrix, with a lysate or other solution containing STEAP under conditions which permit the STEAP antibody to bind to STEAP; washing the solid matrix to eliminate impurities; and eluting the STEAP from the coupled antibody. Other uses of the STEAP antibodies of the invention include generating anti-idiotypic antibodies that mimic the STEAP protein.

5

Various methods for the preparation of antibodies are well known in the art. For example, antibodies may be prepared by immunizing a suitable mammalian host using a STEAP protein, peptide, or fragment, in isolated or immunoconjugated form (Antibodies: A Laboratory Manual, CSH Press, Eds., Harlow, and Lane (1988); Harlow, Antibodies, Cold Spring Harbor Press, NY (1989)).

10 In addition, fusion proteins of STEAP may also be used, such as a STEAP GST-fusion protein. In a particular embodiment, a GST fusion protein comprising all or most of the open reading frame amino acid sequence of a STEAP may be produced and used as an immunogen to generate appropriate antibodies. In another embodiment, a STEAP peptide may be synthesized and used as an immunogen. As described in Example 5, below, the 15-mer STEAP peptide  
15 HSSKEKLRRERIKYC was conjugated to keyhole limpet hemocyanin (KLH) and used to immunize a rabbit. The resulting polyclonal antiserum specifically recognized STEAP expressed in a recombinant mammalian expression system.

In addition, naked DNA immunization techniques known in the art may be used (with or without  
20 purified STEAP protein or STEAP expressing cells) to generate an immune response to the encoded immunogen (for review, see Donnelly et al., 1997, Ann. Rev. Immunol. 15: 617-648).

The amino acid sequences of the STEAPs provided herein may be used to select specific regions of the STEAP protein for generating antibodies. For example, hydrophobicity and hydrophilicity  
25 analyses of the STEAP amino acid sequence may be used to identify hydrophilic regions in the STEAP structure. Regions of the STEAP protein that show immunogenic structure, as well as other regions and domains, can readily be identified using various other methods known in the art, such as Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis. Methods for the generation of STEAP antibodies are further illustrated by way of the  
30 examples provided herein.

Methods for preparing a protein or polypeptide for use as an immunogen and for preparing immunogenic conjugates of a protein with a carrier such as BSA, KLH, or other carrier proteins are well known in the art. In some circumstances, direct conjugation using, for example, carbodiimide  
35 reagents may be used; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, may be effective. Administration of a STEAP immunogen is conducted generally by injection over a suitable time period and with use of a suitable adjuvant, as is generally

understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of antibody formation.

5 STEAP monoclonal antibodies are preferred and may be produced by various means well known in the art. For example, immortalized cell lines which secrete a desired monoclonal antibody may be prepared using the standard hybridoma technology of Kohler and Milstein or modifications which immortalize producing B cells, as is generally known. The immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the STEAP protein or a STEAP fragment. When the appropriate immortalized cell culture secreting the desired antibody is  
10 identified, the cells may be expanded and antibodies produced either from in vitro cultures or from ascites fluid.

The antibodies or fragments may also be produced, using current technology, by recombinant means. Regions that bind specifically to the desired regions of the STEAP protein can also be  
15 produced in the context of chimeric or CDR grafted antibodies of multiple species origin. Humanized or human STEAP antibodies may also be produced and are preferred for use in therapeutic contexts. Methods for humanizing murine and other non-human antibodies by substituting one or more of the non-human antibody CDRs for corresponding human antibody sequences are well known (see for example, Jones et al., 1986, Nature 321: 522-525; Riechmnan  
20 et al., 1988, Nature 332: 323-327; Verhoeyen et al., 1988, Science 239: 1534-1536). See also, Carter et al., 1993, Proc. Natl. Acad. Sci. USA 89: 4285 and Sims et al., 1993, J. Immunol. 151: 2296. Methods for producing fully human monoclonal antibodies include phage display and transgenic methods (for review, see Vaughan et al., 1998, Nature Biotechnology 16: 535-539).

25 Fully human STEAP monoclonal antibodies may be generated using cloning technologies employing large human Ig gene combinatorial libraries (i.e., phage display) (Griffiths and Hoogenboom, Building an in vitro immune system: human antibodies from phage display libraries. In: Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man. Clark, M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and Barbas, Human Antibodies from  
30 combinatorial libraries. *Id.*, pp 65-82). Fully human STEAP monoclonal antibodies may also be produced using transgenic mice engineered to contain human immunoglobulin gene loci as described in PCT Patent Application WO98/24893, Kucherlapati and Jakobovits et al., published December 3, 1997 (see also, Jakobovits, 1998, Exp. Opin. Invest. Drugs 7(4): 607-614). This method avoids the in vitro manipulation required with phage display technology and efficiently  
35 produces high affinity authentic human antibodies.



Reactivity of STEAP antibodies with a STEAP protein may be established by a number of well known means, including Western blot, immunoprecipitation, ELISA, and FACS analyses using, as appropriate, STEAP proteins, peptides, STEAP-expressing cells or extracts thereof.

- 5 A STEAP antibody or fragment thereof of the invention may be labeled with a detectable marker or conjugated to a second molecule. Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme. Further, bi-specific antibodies specific for two or more STEAP epitopes may be generated using methods generally known in the art. Homodimeric  
10 antibodies may also be generated by cross-linking techniques known in the art (e.g., Wolff et al., Cancer Res. 53: 2560-2565).

#### **METHODS FOR THE DETECTION OF STEAP**

- Another aspect of the present invention relates to methods for detecting STEAP polynucleotides and  
15 STEAP proteins, as well as methods for identifying a cell which expresses STEAP.

- More particularly, the invention provides assays for the detection of STEAP polynucleotides in a biological sample, such as serum, bone, prostate, and other tissues, urine, semen, cell preparations, and the like. Detectable STEAP polynucleotides include, for example, a STEAP gene or fragments  
20 thereof, STEAP mRNA, alternative splice variant STEAP mRNAs, and recombinant DNA or RNA molecules containing a STEAP polynucleotide. A number of methods for amplifying and/or detecting the presence of STEAP polynucleotides are well known in the art and may be employed in the practice of this aspect of the invention.

- 25 In one embodiment, a method for detecting a STEAP mRNA in a biological sample comprises producing cDNA from the sample by reverse transcription using at least one primer; amplifying the cDNA so produced using a STEAP polynucleotides as sense and antisense primers to amplify STEAP cDNAs therein; and detecting the presence of the amplified STEAP cDNA. In another embodiment, a method of detecting a STEAP gene in a biological sample comprises first isolating  
30 genomic DNA from the sample; amplifying the isolated genomic DNA using STEAP polynucleotides as sense and antisense primers to amplify the STEAP gene therein; and detecting the presence of the amplified STEAP gene. Any number of appropriate sense and antisense probe combinations may be designed from the nucleotide sequences provided for STEAP-1 (FIG. 1A), STEAP-2 (FIG. 9), STEAP-3 (FIG. 10A), or STEAP-4 (FIG. 10B), as appropriate, and used for  
35 this purpose.

The invention also provides assays for detecting the presence of a STEAP protein in a tissue of other biological sample such as serum, bone, prostate, and other tissues, urine, cell preparations,

and the like. Methods for detecting a STEAP protein are also well known and include, for example, immunoprecipitation, immunohistochemical analysis, Western Blot analysis, molecular binding assays, ELISA, ELIFA and the like.

- 5 For example, in one embodiment, a method of detecting the presence of a STEAP protein in a biological sample comprises first contacting the sample with a STEAP antibody, a STEAP-reactive fragment thereof, or a recombinant protein containing an antigen binding region of a STEAP antibody; and then detecting the binding of STEAP protein in the sample thereto.
- 10 Methods for identifying a cell which expresses STEAP are also provided. In one embodiment, an assay for identifying a cell which expresses a STEAP gene comprises detecting the presence of STEAP mRNA in the cell. Methods for the detection of particular mRNAs in cells are well known and include, for example, hybridization assays using complementary DNA probes (such as in situ hybridization using labeled STEAP riboprobes, Northern blot and related techniques) and various
- 15 nucleic acid amplification assays (such as RT-PCR using complementary primers specific for STEAP, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like). Alternatively, an assay for identifying a cell which expresses a STEAP gene comprises detecting the presence of STEAP protein in the cell or secreted by the cell. Various methods for the detection of proteins are well known in the art and may be employed for the detection of STEAP
- 20 proteins and STEAP expressing cells.

- STEAP expression analysis may also be useful as a tool for identifying and evaluating agents which modulate STEAP gene expression. For example, STEAP-1 expression is significantly upregulated in colon, bladder, pancreatic, ovarian and other cancers. Identification of a molecule or biological
- 25 agent that could inhibit STEAP-1 over-expression may be of therapeutic value in the treatment of cancer. Such an agent may be identified by using a screen that quantifies STEAP expression by RT-PCR, nucleic acid hybridization or antibody binding.

#### **ASSAYS FOR DETERMINING STEAP EXPRESSION STATUS**

- 30 Determining the status of STEAP expression patterns in an individual may be used to diagnose cancer and may provide prognostic information useful in defining appropriate therapeutic options. Similarly, the expression status of STEAP may provide information useful for predicting susceptibility to particular disease stages, progression, and/or tumor aggressiveness. The invention provides methods and assays for determining STEAP expression status and diagnosing cancers which
- 35 express STEAP.

In one aspect, the invention provides assays useful in determining the presence of cancer in an individual, comprising detecting a significant increase in STEAP mRNA or protein expression in a

test cell or tissue sample relative to expression levels in the corresponding normal cell or tissue. In one embodiment, the presence of STEAP-1 mRNA is evaluated in tissue samples of the colon, pancreas, bladder, ovary, cervix, testis or breast. The presence of significant STEAP-1 expression in any of these tissues may be useful to indicate the emergence, presence and/or severity of these cancers, since the corresponding normal tissues do not express STEAP-1 mRNA. In a related embodiment, STEAP-1 expression status may be determined at the protein level rather than at the nucleic acid level. For example, such a method or assay would comprise determining the level of STEAP-1 protein expressed by cells in a test tissue sample and comparing the level so determined to the level of STEAP expressed in a corresponding normal sample. In one embodiment, the presence of STEAP-1 protein is evaluated, for example, using immunohistochemical methods. STEAP antibodies or binding partners capable of detecting STEAP protein expression may be used in a variety of assay formats well known in the art for this purpose.

Peripheral blood may be conveniently assayed for the presence of cancer cells, including prostate, colon, pancreatic, bladder and ovarian cancers, using RT-PCR to detect STEAP-1 expression. The presence of RT-PCR amplifiable STEAP-1 mRNA provides an indication of the presence of one of these types of cancer. RT-PCR detection assays for tumor cells in peripheral blood are currently being evaluated for use in the diagnosis and management of a number of human solid tumors. In the prostate cancer field, these include RT-PCR assays for the detection of cells expressing PSA and PSM (Verkaik et al., 1997, Urol. Res. 25: 373-384; Ghossein et al., 1995, J. Clin. Oncol. 13: 1195-2000; Heston et al., 1995, Clin. Chem. 41: 1687-1688). RT-PCR assays are well known in the art.

In another approach, a recently described sensitive assay for detecting and characterizing carcinoma cells in blood may be used (Racila et al., 1998, Proc. Natl. Acad. Sci. USA 95: 4589-4594). This assay combines immunomagnetic enrichment with multiparameter flow cytometric and immunohistochemical analyses, and is highly sensitive for the detection of cancer cells in blood, reportedly capable of detecting one epithelial cell in 1 ml of peripheral blood.

A related aspect of the invention is directed to predicting susceptibility to developing cancer in an individual. In one embodiment, a method for predicting susceptibility to cancer comprises detecting STEAP mRNA or STEAP protein in a tissue sample, its presence indicating susceptibility to cancer, wherein the degree of STEAP mRNA expression present is proportional to the degree of susceptibility.

Yet another related aspect of the invention is directed to methods for gauging tumor aggressiveness. In one embodiment, a method for gauging aggressiveness of a tumor comprises determining the level of STEAP mRNA or STEAP protein expressed by cells in a sample of the tumor, comparing the level so determined to the level of STEAP mRNA or STEAP protein expressed

in a corresponding normal tissue taken from the same individual or a normal tissue reference sample, wherein the degree of STEAP mRNA or STEAP protein expression in the tumor sample relative to the normal sample indicates the degree of aggressiveness.

- 5 Methods for detecting and quantifying the expression of STEAP mRNA or protein are described herein and use standard nucleic acid and protein detection and quantification technologies well known in the art. Standard methods for the detection and quantification of STEAP mRNA include in situ hybridization using labeled STEAP riboprobes, Northern blot and related techniques using STEAP polynucleotide probes, RT-PCR analysis using primers specific for STEAP, and other  
10 amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like. In a specific embodiment, semi-quantitative RT-PCR may be used to detect and quantify STEAP mRNA expression as described in the Examples which follow. Any number of primers capable of amplifying STEAP may be used for this purpose, including but not limited to the various primer sets specifically described herein. Standard methods for the detection and quantification of  
15 protein may be used for this purpose. In a specific embodiment, polyclonal or monoclonal antibodies specifically reactive with the wild-type STEAP protein may be used in an immunohistochemical assay of biopsied tissue.

#### **DIAGNOSTIC IMAGING OF HUMAN CANCERS**

- 20 Antibodies specific for STEAPs may be particularly useful in radionuclide and other forms of diagnostic imaging of certain cancers, given their expression profiles and cell surface location. For example, immunohistochemical analysis of STEAP-1 protein suggests that in normal tissues STEAP-1 is predominantly restricted to prostate and bladder. The transmembrane orientation of STEAP-1 (and presumably STEAP-2, STEAP-3, STEAP-4) provides a target readily identifiable by  
25 antibodies specifically reactive with extracellular epitopes. This tissue restricted expression, and the localization of STEAP to the cell surface of multiple cancers makes STEAP an ideal candidate for diagnostic imaging. Accordingly, in vivo imaging techniques may be used to image human cancers expressing a STEAP protein.
- 30 For example, cell surface STEAP-1 protein is expressed at very high levels in several human cancers, particularly prostate, bladder, colon and ovarian cancers, and Ewing sarcoma. Moreover, in normal tissues, STEAP-1 protein expression is largely restricted to prostate. Thus, radiolabeled antibodies specifically reactive with extracellular epitopes of STEAP-1 may be particularly useful in vivo imaging of solid tumors of the foregoing cancers. Such labeled anti-  
35 STEAP-1 antibodies may provide very high level sensitivities for the detection of metastasis of these cancers.

Preferably, monoclonal antibodies are used in the diagnostic imaging methods of the invention.

## **CANCER IMMUNOTHERAPY AND CANCER VACCINES**

The invention provides various immunotherapeutic methods for treating prostate cancer, including antibody therapy, in vivo vaccines, and ex vivo immunotherapy methods, which utilize polynucleotides and polypeptides corresponding to STEAP and STEAP antibodies. These therapeutic applications are described further in the following subsections.

### **ANTIBODY THERAPY**

The cell surface nature and expression profiles of the STEAPs in cancers including prostate cancer indicate that they are promising targets for antibody therapy of prostate and other cancers expressing STEAPs. The experimental results described in the Examples herein provide compelling evidence that STEAP-1 is strongly expressed uniformly over the surface of glandular epithelial cells within prostate and prostate cancer cells. In particular, immunohistochemical analysis results show that the surface of human prostate epithelial cells (normal and cancer) appear to be uniformly coated with STEAP-1. Biochemical analysis confirms the cell surface localization of STEAP-1 initially suggested by its putative 6-transmembrane primary structural elements and by the pericellular staining plainly visualized by immunohistochemical staining.

STEAP-1 is uniformly expressed at high levels over the surface of prostate glandular epithelia, an ideal situation for immunotherapeutic intervention strategies which target extracellular STEAP epitopes. Systemic administration of STEAP-immunoreactive compositions would be expected to result in extensive contact of the composition with prostate epithelial cells via binding to STEAP-1 extracellular epitopes. Moreover, given the near absence of STEAP-1 protein expression in normal human tissues, there is ample reason to expect exquisite sensitivity without toxic, non-specific and/or non-target effects caused by the binding of the immunotherapeutic composition to STEAP-1 on non-target organs and tissues.

In addition to the high level expression of STEAP-1 in prostate and prostate cancer cells, STEAP-1 appears to be substantially over-expressed in a variety of other human cancers, including bladder, colon, pancreatic and ovarian cancers. In particular, high level STEAP-1 mRNA expression is detected in all tested prostate cancer tissues and cell lines, and in most of the pancreatic, colon, and bladder cancer cell lines tested. High level expression of STEAP-1 is also observed in some ovarian cancer cell lines. Lower level expression is observed in some breast, testicular, and cervical cancer cell lines. Very high level expression is also detected in a Ewing sarcoma cell line. Applicants have shown that cell surface STEAP-1 protein is expressed in bladder and colon cancers, while there is no detectable cell surface (or intracellular) STEAP-1 protein in normal colon and low expression in normal bladder. Antibodies specifically reactive with extracellular domains of STEAP-1

may be useful to treat these cancers systemically, either as toxin or therapeutic agent conjugates or as naked antibodies capable of inhibiting cell proliferation or function.

5 STEAP-2 protein is also expressed in prostate cancer, and may be expressed in other cancers as well. STEAP-2 mRNA analysis by RT-PCR and Northern blot show that expression is restricted to prostate in normal tissues, is also expressed in some prostate, pancreatic, colon, testicular, ovarian and other cancers. Therefore, antibodies reactive with STEAP-2 may be useful in the treatment of prostate and other cancers. Similarly, although not yet characterized by applicants, the expression of STEAP-3 and STEAP-4 (as well as other STEAPs) may be associated with some cancers. Thus  
10 antibodies reactive with these STEAP family member proteins may also be useful therapeutically.

STEAP antibodies may be introduced into a patient such that the antibody binds to STEAP on the cancer cells and mediates the destruction of the cells and the tumor and/or inhibits the growth of the cells or the tumor. Mechanisms by which such antibodies exert a therapeutic effect may include  
15 complement-mediated cytolysis, antibody-dependent cellular cytotoxicity, modulating the physiologic function of STEAP, inhibiting ligand binding or signal transduction pathways, modulating tumor cell differentiation, altering tumor angiogenesis factor profiles, and/or by inducing apoptosis. STEAP antibodies conjugated to toxic or therapeutic agents may also be used therapeutically to deliver the toxic or therapeutic agent directly to STEAP-bearing tumor cells.

20 Cancer therapy using anti-STEAP antibodies may follow the teachings generated from various approaches which have been successfully employed with respect to other types of cancer, including but not limited to colon cancer (Arlen et al., 1998, Crit Rev Immunol 18: 133-138), multiple myeloma (Ozaki et al., 1997, Blood 90: 3179-3186; Tsunenari et al., 1997, Blood 90: 2437-2444),  
25 gastric cancer (Kasprzyk et al., 1992, Cancer Res 52: 2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J Immunother Emphasis Tumor Immunol 19: 93-101), leukemia (Zhong et al., 1996, Leuk Res 20: 581-589), colorectal cancer (Moun et al., 1994, Cancer Res 54: 6160-6166); Velders et al., 1995, Cancer Res 55: 4398-4403), and breast cancer (Shepard et al., 1991, J Clin Immunol 11: 117-127).

30 Although STEAP antibody therapy may be useful for all stages of the foregoing cancers, antibody therapy may be particularly appropriate and in advanced or metastatic cancers. Combining the antibody therapy method of the invention with a chemotherapeutic or radiation regimen may be preferred in patients who have not received chemotherapeutic treatment, whereas treatment with  
35 the antibody therapy of the invention may be indicated for patients who have received one or more chemotherapy. Additionally, antibody therapy may also enable the use of reduced dosages of concomitant chemotherapy, particularly in patients that do not tolerate the toxicity of the chemotherapeutic agent very well.

It may be desirable for non-prostate cancer patients to be evaluated for the presence and level of STEAP over-expression, preferably using immunohistochemical assessments of tumor tissue, quantitative STEAP imaging, or other techniques capable of reliably indicating the presence and degree of STEAP overexpression. Immunohistochemical analysis of tumor biopsies or surgical specimens may be preferred for this purpose. Methods for immunohistochemical analysis of tumor tissues are well known in the art.

Anti-STEAP monoclonal antibodies useful in treating prostate and other cancers include those which are capable of initiating a potent immune response against the tumor and those which are capable of direct cytotoxicity. In this regard, anti-STEAP mAbs may elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites or complement proteins. In addition, anti-STEAP mAbs which exert a direct biological effect on tumor growth are useful in the practice of the invention. Potential mechanisms by which such directly cytotoxic mAbs may act include inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism by which a particular anti-STEAP mAb exerts an anti-tumor effect may be evaluated using any number of in vitro assays designed to determine ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is generally known in the art.

The anti-tumor activity of a particular anti-STEAP mAb, or combination of anti-STEAP mAbs, may be evaluated in vivo using a suitable animal model. For example, xenogenic prostate cancer models wherein human prostate cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice, are appropriate in relation to prostate cancer and have been described (Klein et al., 1997, Nature Medicine 3: 402-408). For Example, PCT Patent Application WO98/16628, Sawyers et al., published April 23, 1998, describes various xenograft models of human prostate cancer capable of recapitulating the development of primary tumors, micrometastasis, and the formation of osteoblastic metastases characteristic of late stage disease. Efficacy may be predicted using assays which measure inhibition of tumor formation, tumor regression or metastasis, and the like.

It should be noted that the use of murine or other non-human monoclonal antibodies, human/mouse chimeric mAbs may induce moderate to strong immune responses in some patients. In the most severe cases, such an immune response may lead to the extensive formation of immune complexes which, potentially, can cause renal failure. Accordingly, preferred monoclonal antibodies used in the practice of the therapeutic methods of the invention are those which are

either fully human or humanized and which bind specifically to the target 20P1F12/TMPRSS2 antigen with high affinity but exhibit low or no antigenicity in the patient.

5 The method of the invention contemplates the administration of single anti-STEAP mAbs as well as combinations, or "cocktails, of different mAbs. Such mAb cocktails may have certain advantages inasmuch as they contain mAbs which exploit different effector mechanisms or combine directly cytotoxic mAbs with mAbs that rely on immune effector functionality. Such mAbs in combination may exhibit synergistic therapeutic effects. In addition, the administration of anti-STEAP mAbs may be combined with other therapeutic agents, including but not limited to various chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL-2, GM-CSF). The anti-STEAP mAbs may be administered in their "naked" or unconjugated form, or may have therapeutic agents conjugated to them.

15 The anti-STEAP monoclonal antibodies used in the practice of the method of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material which when combined with the anti-STEAP mAbs retains the anti-tumor function of the antibody and is non-reactive with the subject's immune systems. Examples include, but are not limited to, any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like.

20 The anti-STEAP antibody formulations may be administered via any route capable of delivering the antibodies to the tumor site. Potentially effective routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. The preferred route of administration is by intravenous injection. A preferred formulation for intravenous injection comprises the anti-STEAP mAbs in a solution of preserved bacteriostatic water, sterile unpreserved water, and/or diluted in polyvinylchloride or polyethylene bags containing 0.9% sterile Sodium Chloride for Injection, USP. The anti-STEAP mAb preparation may be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.

30 Treatment will generally involve the repeated administration of the anti-STEAP antibody preparation via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1 to about 10 mg/kg body weight. Doses in the range of 10-500 mg mAb per week may be effective and well tolerated. Based on clinical experience with the Herceptin mAb in the treatment of metastatic breast cancer, an initial loading dose of approximately 4 mg/kg patient body weight IV followed by weekly doses of about 2 mg/kg IV of the anti- STEAP mAb preparation may represent an acceptable dosing regimen. Preferably, the initial loading dose is administered as



a 90 minute or longer infusion. The periodic maintenance dose may be administered as a 30 minute or longer infusion, provided the initial dose was well tolerated. However, as one of skill in the art will understand, various factors will influence the ideal dose regimen in a particular case. Such factors may include, for example, the binding affinity and half life of the mAb or mAbs used, the degree of STEAP overexpression in the patient, the extent of circulating shed STEAP antigen, the desired steady-state antibody concentration level, frequency of treatment, and the influence of chemotherapeutic agents used in combination with the treatment method of the invention.

Optimally, patients should be evaluated for the level of circulating shed STEAP antigen in serum in order to assist in the determination of the most effective dosing regimen and related factors. Such evaluations may also be used for monitoring purposes throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters (such as serum PSA levels in prostate cancer therapy).

### **CANCER VACCINES**

The invention further provides prostate cancer vaccines comprising a STEAP protein or fragment thereof. The use of a tumor antigen in a vaccine for generating humoral and cell-mediated immunity for use in anti-cancer therapy is well known in the art and has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63: 231-237; Fong et al., 1997, J. Immunol. 159: 3113-3117). Such methods can be readily practiced by employing a STEAP protein, or fragment thereof, or a STEAP-encoding nucleic acid molecule and recombinant vectors capable of expressing and appropriately presenting the STEAP immunogen.

For example, viral gene delivery systems may be used to deliver a STEAP-encoding nucleic acid molecule. Various viral gene delivery systems which can be used in the practice of this aspect of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbus virus (Restifo, 1996, Curr. Opin. Immunol. 8: 658-663). Non-viral delivery systems may also be employed by using naked DNA encoding a STEAP protein or fragment thereof introduced into the patient (e.g., intramuscularly) to induce an anti-tumor response. In one embodiment, the full-length human STEAP cDNA may be employed. In another embodiment, STEAP nucleic acid molecules encoding specific cytotoxic T lymphocyte (CTL) epitopes may be employed. CTL epitopes can be determined using specific algorithms (e.g., Epimer, Brown University) to identify peptides within a STEAP protein which are capable of optimally binding to specified HLA alleles. Optimally immunogenic HLA Class I molecule-binding peptides within the STEAP-1 and STEAP-2 sequences have been analyzed in Example 9, below.

Various ex vivo strategies may also be employed. One approach involves the use of dendritic cells to present STEAP antigen to a patient's immune system. Dendritic cells express MHC class I and II, B7 costimulator, and IL-12, and are thus highly specialized antigen presenting cells. In prostate cancer, autologous dendritic cells pulsed with peptides of the prostate-specific membrane antigen (PSMA) are being used in a Phase I clinical trial to stimulate prostate cancer patients' immune systems (Tjoa et al., 1996, Prostate 28: 65-69; Murphy et al., 1996, Prostate 29: 371-380). Dendritic cells can be used to present STEAP peptides to T cells in the context of MHC class I and II molecules. In one embodiment, autologous dendritic cells are pulsed with STEAP peptides capable of binding to MHC molecules. In another embodiment, dendritic cells are pulsed with the complete STEAP protein. Yet another embodiment involves engineering the overexpression of the STEAP gene in dendritic cells using various implementing vectors known in the art, such as adenovirus (Arthur et al., 1997, Cancer Gene Ther. 4: 17-25), retrovirus (Henderson et al., 1996, Cancer Res. 56: 3763-3770), lentivirus, adeno-associated virus, DNA transfection (Ribas et al., 1997, Cancer Res. 57: 2865-2869), and tumor-derived RNA transfection (Ashley et al., 1997, J. Exp. Med. 186: 1177-1182).

Anti-idiotypic anti-STEAP antibodies can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing a STEAP protein. Specifically, the generation of anti-idiotypic antibodies is well known in the art and can readily be adapted to generate anti-idiotypic anti-STEAP antibodies that mimic an epitope on a STEAP protein (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J Clin Invest 96: 334-342; Herlyn et al., 1996, Cancer Immunol Immunother 43: 65-76). Such an anti-idiotypic antibody can be used in anti-idiotypic therapy as presently practiced with other anti-idiotypic antibodies directed against tumor antigens.

Genetic immunization methods may be employed to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing STEAP. Constructs comprising DNA encoding a STEAP protein/immunogen and appropriate regulatory sequences may be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded STEAP protein/immunogen. Expression of the STEAP protein immunogen results in the generation of prophylactic or therapeutic humoral and cellular immunity against prostate cancer. Various prophylactic and therapeutic genetic immunization techniques known in the art may be used (for review, see information and references published at Internet address [www.genweb.com](http://www.genweb.com)).

### **KITS**

For use in the diagnostic and therapeutic applications described or suggested above, kits are also provided by the invention. Such kits may comprise a carrier means being compartmentalized to

receive in close confinement one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method. For example, one of the container means may comprise a probe which is or can be detectably labeled. Such probe may be an antibody or polynucleotide specific for a STEAP protein or a STEAP gene or message, respectively. Where the kit utilizes nucleic acid hybridization to detect the target nucleic acid, the kit may also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence and/or a container comprising a reporter-means, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an enzymatic, florescent, or radionucleotide label.

## **EXAMPLES**

Various aspects of the invention are further described and illustrated by way of the several examples which follow, none of which are intended to limit the scope of the invention.

### **EXAMPLE 1:**

#### **ISOLATION OF cDNA FRAGMENT OF STEAP-1 GENE**

## **MATERIALS AND METHODS**

### **Cell lines and Human Tissues**

All human cancer cell lines used in this study were obtained from the ATCC. All cell lines were maintained in DMEM with 10% fetal calf serum. PREC (primary prostate epithelial cells) were obtained from Clonetics and were grown in PREBM media supplemented with growth factors (Clonetics).

All human prostate cancer xenografts were originally provided by Charles Sawyers (UCLA) (Klein et al., 1997). LAPC-4 AD and LAPC-9 AD xenografts were routinely passaged as small tissue chunks in recipient SCID males. LAPC-4 AI and LAPC-9 AI xenografts were derived as described previously (Klein et al., 1997) and were passaged in castrated males or in female SCID mice. A benign prostatic hyperplasia tissue sample was patient-derived.

Human tissues for RNA and protein analyses were obtained from the Human Tissue Resource Center (HTRC) at the UCLA (Los Angeles, CA) and from QualTek, Inc. (Santa Barbara, CA).

### **RNA Isolation:**

Tumor tissue and cell lines were homogenized in Trizol reagent (Life Technologies, Gibco BRL) using 10 ml/ g tissue or 10 ml/ 10<sup>8</sup> cells to isolate total RNA. Poly A RNA was purified from total RNA using Qiagen's Oligotex mRNA Mini and Midi kits. Total and mRNA were quantified by spectrophotometric analysis (O.D. 260/280 nm) and analyzed by gel electrophoresis.

### **Oligonucleotides:**

The following HPLC purified oligonucleotides were used.

10 RSACDN (cDNA synthesis primer):

5'TTTT**GTACA**AGCTT<sub>30</sub>3'

Adaptor 1:

5'CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAG**GT**3'

15

3'GGCCCGT**CCA**5'

Adaptor 2:

5'GTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAG**GT**3'

3'CGGCT**CCA**5'

PCR primer 1:

20

5'CTAATACGACTCACTATAGGGC3'

Nested primer (NP)1:

5'TCGAGCGGCCGCCCGGGCAG**GT**3'

25

Nested primer (NP)2:

5'AGCGTGGTCGCGGCCGAG**GT**3'

### **Suppression Subtractive Hybridization:**

Suppression Subtractive Hybridization (SSH) was used to identify cDNAs corresponding to genes which may be up-regulated in androgen dependent prostate cancer compared to benign prostatic hyperplasia.

Double stranded cDNAs corresponding to the LAPC-4 AD xenograft (tester) and the BPH tissue (driver) were synthesized from 2 µg of poly(A)<sup>+</sup> RNA isolated from xenograft and BPH tissue, as described above, using CLONTECH's PCR-Select cDNA Subtraction Kit and 1 ng of oligonucleotide RSACDN as primer. First- and second-strand synthesis were carried out as described in the Kit's user manual protocol (CLONTECH Protocol No. PT1117-1, Catalog No. K1804-1). The resulting

cDNA was digested with Rsa I for 3 hrs. at 37°C. Digested cDNA was extracted with phenol/chloroform (1:1) and ethanol precipitated.

Driver cDNA (BPH) was generated by combining in a 4 to 1 ratio Rsa I digested BPH cDNA with digested cDNA from mouse liver, in order to ensure that murine genes were subtracted from the tester cDNA (LAPC-4 AD).

Tester cDNA (LAPC-4 AD) was generated by diluting 1 µl of Rsa I digested LAPC-4 AD cDNA (400 ng) in 5 µl of water. The diluted cDNA (2 µl, 160 ng) was then ligated to 2 µl of adaptor 1 and adaptor 2 (10 µM), in separate ligation reactions, in a total volume of 10 µl at 16°C overnight, using 400 u of T4 DNA ligase (CLONTECH). Ligation was terminated with 1 µl of 0.2 M EDTA and heating at 72°C for 5 min.

The first hybridization was performed by adding 1.5 µl (600 ng) of driver cDNA to each of two tubes containing 1.5 µl (20 ng) adaptor 1- and adaptor 2- ligated tester cDNA. In a final volume of 4 µl, the samples were overlaid with mineral oil, denatured in an MJ Research thermal cycler at 98°C for 1.5 minutes, and then were allowed to hybridize for 8 hrs at 68°C. The two hybridizations were then mixed together with an additional 1 µl of fresh denatured driver cDNA and were allowed to hybridize overnight at 68°C. The second hybridization was then diluted in 200 µl of 20 mM Hepes, pH 8.3, 50 mM NaCl, 0.2 mM EDTA, heated at 70°C for 7 min. and stored at -20°C.

#### **PCR Amplification, Cloning and Sequencing of Gene Fragments Generated from SSH:**

To amplify gene fragments resulting from SSH reactions, two PCR amplifications were performed. In the primary PCR reaction 1 µl of the diluted final hybridization mix was added to 1 µl of PCR primer 1 (10 µM), 0.5 µl dNTP mix (10 µM), 2.5 µl 10 x reaction buffer (CLONTECH) and 0.5 µl 50 x Advantage cDNA polymerase Mix (CLONTECH) in a final volume of 25 µl. PCR 1 was conducted using the following conditions: 75°C for 5 min., 94°C for 25 sec., then 27 cycles of 94°C for 10 sec, 66°C for 30 sec, 72°C for 1.5 min. Five separate primary PCR reactions were performed for each experiment. The products were pooled and diluted 1:10 with water. For the secondary PCR reaction, 1 µl from the pooled and diluted primary PCR reaction was added to the same reaction mix as used for PCR 1, except that primers NP1 and NP2 (10 µM) were used instead of PCR primer 1. PCR 2 was performed using 10-12 cycles of 94°C for 10 sec, 68°C for 30 sec, 72°C for 1.5 minutes. The PCR products were analyzed using 2% agarose gel electrophoresis.

The PCR products were inserted into pCR2.1 using the T/A vector cloning kit (Invitrogen). Transformed E. coli were subjected to blue/white and ampicillin selection. White colonies were picked and arrayed into 96 well plates and were grown in liquid culture overnight. To identify inserts, PCR amplification was performed on 1 ml of bacterial culture using the conditions of PCR1 and NP1 and NP2 as primers. PCR products were analyzed using 2% agarose gel electrophoresis.

Bacterial clones were stored in 20% glycerol in a 96 well format. Plasmid DNA was prepared, sequenced, and subjected to nucleic acid homology searches of the GenBank, dBest, and NCI-CGAP databases.

### **RT-PCR Expression Analysis:**

First strand cDNAs were generated from 1 µg of mRNA with oligo (dT)12-18 priming using the Gibco-BRL Superscript Preamplification system. The manufacturers protocol was used and included an incubation for 50 min at 42°C with reverse transcriptase followed by RNase H treatment at 37°C for 20 min. After completing the reaction, the volume was increased to 200 µl with water prior to normalization. First strand cDNAs from 16 different normal human tissues were obtained from Clontech.

Normalization of the first strand cDNAs from multiple tissues was performed by using the primers 5'atatcgccgcgctcgtcgtcgacaa3' and 5'agccacacgcagctcattgtagaagg 3' to amplify β-actin. First strand cDNA (5 µl) was amplified in a total volume of 50 µl containing 0.4 µM primers, 0.2 µM each dNTPs, 1XPCR buffer (Clontech, 10 mM Tris-HCL, 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, pH8.3) and 1X KlenTaq DNA polymerase (Clontech). Five µl of the PCR reaction was removed at 18, 20, and 22 cycles and used for agarose gel electrophoresis. PCR was performed using an MJ Research thermal cycler under the following conditions: initial denaturation was at 94°C for 15 sec, followed by a 18, 20, and 22 cycles of 94°C for 15, 65°C for 2 min, 72°C for 5 sec. A final extension at 72°C was carried out for 2 min. After agarose gel electrophoresis, the band intensities of the 283 bp β-actin bands from multiple tissues were compared by visual inspection. Dilution factors for the first strand cDNAs were calculated to result in equal β-actin band intensities in all tissues after 22 cycles of PCR. Three rounds of normalization were required to achieve equal band intensities in all tissues after 22 cycles of PCR.

To determine expression levels of the 8P1D4 gene, 5 µl of normalized first strand cDNA was analyzed by PCR using 25, 30, and 35 cycles of amplification using the following primer pairs, which were designed with the assistance of (MIT; for details, see, [www.genome.wi.mit.edu](http://www.genome.wi.mit.edu)):

5' ACT TTG TTG ATG ACC AGG ATT GGA 3'  
 5' CAG AAC TTC AGC ACA CAC AGG AAC 3'

5

Semi quantitative expression analysis was achieved by comparing the PCR products at cycle numbers that give light band intensities.

## RESULTS:

- 10 Several SSH experiments were conducted as described in the Materials and Methods, supra, and led to the isolation of numerous candidate gene fragment clones. All candidate clones were sequenced and subjected to homology analysis against all sequences in the major public gene and EST databases in order to provide information on the identity of the corresponding gene and to help guide the decision to analyze a particular gene for differential expression. In general,
- 15 gene fragments which had no homology to any known sequence in any of the searched databases, and thus considered to represent novel genes, as well as gene fragments showing homology to previously sequenced expressed sequence tags (ESTs), were subjected to differential expression analysis by RT-PCR and/or Northern analysis.
- 20 One of the cDNA clones, designated 8P1D4, was 436 bp in length and showed homology to an EST sequence in the NCI-CGAP tumor gene database. The full length cDNA encoding the 8P1D4 gene was subsequently isolated using this cDNA and re-named STEAP-1. The 8P1D4 cDNA nucleotide sequence corresponds to nucleotide residues 150 through 585 in the STEAP-1 cDNA sequence as shown in FIG. 1A. Another clone, designated 28P3E1, 561 bp in length showed
- 25 homology to a number of EST sequences in the NCI-CGAP tumor gene database or in other databases. Part of the 28P3E1 sequence (356 bp) is identical to an EST derived from human fetal tissue. After the full length STEAP-1 cDNA was obtained and sequenced, it became apparent that this clone also corresponds to STEAP-1 (more specifically, to residues 622 through the 3' end of the STEAP-1 nucleotide sequence as shown in FIG. 1A).
- 30 Differential expression analysis by RT-PCR using primers derived from the 8P1D4 cDNA clone showed that the 8P1D4 (STEAP-1) gene is expressed at approximately equal levels in normal prostate and the LAPC-4 and LAPC-9 xenografts (FIG. 2, panel A). Further RT-PCR expression analysis of first strand cDNAs from 16 normal tissues showed greatest levels of 8P1D4 expression
- 35 in prostate. Substantially lower level expression in several other normal tissues (i.e., colon, ovary, small intestine, spleen and testis) was detectable only at 30 cycles of amplification in brain, pancreas, colon and small intestine (FIG. 2, panels B and C).

## **EXAMPLE 2:**

### **ISOLATION OF FULL LENGTH STEAP-1 ENCODING cDNA**

The 436 bp 8P1D4 gene fragment (Example 1) was used to isolate additional cDNAs encoding the 8P1D4/STEAP-1 gene. Briefly, a normal human prostate cDNA library (Clontech) was screened with a labeled probe generated from the 436 bp 8P1D4 cDNA. One of the positive clones, clone 10, is 1195 bp in length and encodes a 339 amino acid protein having nucleotide and encoded amino acid sequences bearing no significant homology to any known human genes or proteins (homology to a rat Kidney Injury Protein recently described in International Application WO98/53071). The encoded protein contains at least 6 predicted transmembrane motifs implying a cell surface orientation (see FIG. 1A, predicted transmembrane motifs underlined). These structural features led to the designation "STEAP", for "Six Transmembrane Epithelial Antigen of the Prostate". Subsequent identification of additional STEAP proteins led to the re-designation of the 8P1D4 gene product as "STEAP-1". The STEAP-1 cDNA and encoded amino acid sequences are shown in FIG. 1A and correspond to SEQ ID NOS: XX and XX, respectively. STEAP-1 cDNA clone 10 has been deposited with the American Type Culture Collection ("ATCC") (Manassas, VA) as plasmid 8P1D4 clone 10.1 on August 26, 1998 as ATCC Accession Number 98849. The STEAP-1 cDNA clone can be excised therefrom using EcoRI/XbaI double digest (EcoRI at the 5'end, XbaI at the 3'end).

## **EXAMPLE 3:**

### **STEAP-1 GENE AND PROTEIN EXPRESSION ANALYSIS**

In order to begin to characterize the biological characteristics of STEAP-1, an extensive evaluation of STEAP-1 mRNA and STEAP-1 protein expression across a variety of human tissue specimens was undertaken. This evaluation included Northern blot, Western blot and immunohistochemical analysis of STEAP-1 expression in a large number of normal human tissues, human prostate cancer xenografts and cell lines, and various other human cancer cell lines.

#### **Example 3A: Northern Blot Analysis of STEAP-1 mRNA Expression in Normal Human Tissues**

Initial analysis of STEAP-1 mRNA expression in normal human tissues was conducted by Northern blotting two multiple tissue blots obtained from Clontech (Palo Alto, California), comprising a total of 16 different normal human tissues, using labeled STEAP-1 clone 10 as a probe. RNA samples were quantitatively normalized with a  $\beta$ -actin probe. The results are shown in FIG. 3A. The highest expression level was detected in normal prostate, with an approximately 5-10 fold lower level of expression detected in colon and liver. These northern blots showed two transcripts of approximately 1.4 kb and 4.0 kb, the former of which corresponds to the full length



STEAP-1 clone 10 cDNA, which encodes the entire STEAP-1 open reading frame. The larger transcript was separately cloned as a 3627 bp cDNA from a normal prostate library, the sequence of which contains a 2399 bp intron (FIG. 4).

5 This initial analysis was extended by using the STEAP-1 clone 10 probe to analyze an RNA dot blot matrix of 37 normal human tissues (Clontech, Palo Alto, CA; Human Master Blot™). The results are shown in FIG. 3B and show strong STEAP-1 expression only in prostate. Very low level STEAP-1 RNA expression was detected in liver, lung, trachea and fetal liver tissue, at perhaps a 5-fold lower level compared to prostate. No expression was detected in any of the  
10 remaining tissues. Based on these analyses, significant STEAP-1 expression appears to be prostate specific in normal tissues.

### **Example 3B: Northern Blot Analysis of STEAP-1 mRNA Expression in Prostate Cancer Xenografts and Cell Lines**

15 To analyze STEAP-1 expression in human cancer tissues and cell lines, RNAs derived from human prostate cancer xenografts and an extensive panel of prostate and non-prostate cancer cell lines were analyzed by Northern blot using STEAP-1 cDNA clone 10 as probe. All RNA samples were quantitatively normalized by ethidium bromide staining and subsequent analysis with a labeled  $\beta$ -actin probe.

20 The results, presented in FIG. 5, show high level STEAP-1 expression in all the LAPC xenografts and all of the prostate cancer cell lines. Expression in the LAPC-9 xenografts was higher compared to the LAPC-4 xenografts, with no significant difference observed between androgen-dependent and androgen-independent sublines (FIG. 5A). Expression in the LAPC-4 xenografts  
25 was comparable to expression in normal prostate. Lower levels of expression were detected in PrEC cells (Clonetics), which represent the basal cell compartment of the prostate. Analysis of prostate cancer cell lines showed highest expression levels in LNCaP, an androgen dependent prostate carcinoma cell line. Significant expression was also detected in the androgen-independent cell lines PC-3 and DU145. High levels of STEAP expression were also detected in  
30 LAPC-4 and LAPC-9 tumors that were grown within the tibia of mice as a model of prostate cancer bone metastasis (FIG. 5B).

Significantly, very strong STEAP-1 expression was also detected in many of the non-prostate human cancer cell lines analyzed (FIG. 5A). Particularly high level expression was observed in  
35 RD-ES cells, an Ewing sarcoma (EWS) derived cell line. Additionally, very high level expression was also detected in several of the colon cancer cell lines (e.g., CaCo-2, LoVo, T84 and Colo-205), bladder carcinoma cell lines (e.g., SCABER, UM-UC-3, TCCSUP and 5637), ovarian cancer cell lines (e.g., OV-1063 and SW 626) and pancreatic cancer cell lines (e.g., HPAC, Capan-1,

PANC-1 and BxPC-3). These results, combined with the absence of strong expression in the corresponding normal tissues (FIG. 3), indicate that STEAP-1 may be generally up-regulated in these types (as well as other types) of human cancers.

5

### **Example 3C: Western Blot Analysis of STEAP-1 Protein Expression in Prostate and Other Cancers**

10 A 15 mer peptide corresponding to amino acid residues 14 through 28 of the STEAP-1 amino acid sequence as shown in FIG. 1A (WKMKPRRNLEEDDYI) was synthesized and used to immunize sheep for the generation of sheep polyclonal antibodies towards the amino-terminus of the protein (anti-STEAP-1) as follows. The peptide was conjugated to KLH (keyhole limpet hemocyanin). The sheep was initially immunized with 400 µg of peptide in complete Freund's adjuvant. The animal was subsequently boosted every two weeks with 200 µg of peptide in  
15 incomplete Freund's adjuvant. Anti-STEAP antibody was affinity-purified from sheep serum using STEAP peptide coupled to affi-gel 10 (Bio Rad). Purified antibody is stored in phosphate-buffered saline with 0.1% sodium azide.

To test antibody specificity, the cDNA of STEAP-1 was cloned into a retroviral expression vector (pSR $\alpha$ tkneo, Muller et al., 1991, MCB 11:1785). NIH 3T3 cells were infected with retroviruses encoding STEAP-1 and were selected in G418 for 2 weeks. Western blot analysis of protein  
20 extracts of infected and un-infected NIH 3T3 cells showed expression of a protein with an apparent molecular weight of 36 kD only in the infected cells (FIG. 6, lanes marked "3T3 STEAP" AND "3T3").

25

The anti-STEAP-1 polyclonal antibody was used to probe Western blots of cell lysates prepared from a variety of prostate cancer xenograft tissues, prostate cancer cell lines and other non-prostate cancer cell lines. Protein samples (20µg each) were quantitatively normalized by probing the blots with an anti-Grb-2 antibody.

30

The results are shown in FIG. 6. STEAP-1 protein was detected in all of the LAPC prostate cancer xenografts, all of the prostate cancer cell lines, a primary prostate cancer specimen and its matched normal prostate control. Highest STEAP-1 protein expression was detected in the LAPC-9 xenograft and in LNCaP cells, in agreement with the Northern blot analysis described  
35 immediately above. High level expression was also observed in the bladder carcinoma cell line UM-UC-3. Expression in other cancer cell lines was also detectable (FIG. 6).

### **Example 3D: Immunohistochemical Analysis of STEAP-1 Protein Expression in Prostate Tumor Biopsy and Surgical Specimens**

To determine the extent of STEAP-1 protein expression in clinical materials, tissue sections were prepared from a variety of prostate cancer biopsies and surgical samples for immunohistochemical analysis. Tissues were fixed in 10% formalin, embedded in paraffin, and sectioned according to standard protocol. Formalin-fixed, paraffin-embedded sections of LNCaP cells were used as a positive control. Sections were stained with an anti-STEAP-1 polyclonal antibody directed against a STEAP-1 N-terminal epitope (as described immediately above). LNCaP sections were stained in the presence of an excess amount of the STEAP-1 N-terminal peptide immunogen used to generate the polyclonal antibody (peptide 1) or a non-specific peptide derived from a distinct region of the STEAP-1 protein (peptide 2; YQQVQQNKEDAWIEH).

The results are shown in FIG. 8. LNCaP cells showed uniformly strong peri-cellular staining in all cells (FIG. 8b). Excess STEAP N-terminal peptide (peptide 1) was able to competitively inhibit antibody staining (FIG. 8a), while peptide 2 had no effect (FIG. 8b). Similarly, uniformly strong peri-cellular staining was seen in the LAPC-9 (FIG. 8f) and LAPC-4 prostate cancer xenografts (data not shown). These results are clear and suggest that the staining is STEAP specific. Moreover, these results visually localize STEAP to the plasma membrane, corroborating the biochemical findings presented in Example 4 below.

The results obtained with the various clinical specimens are shown in FIG. 8c (normal prostate tissue), FIG. 8d (grade 3 prostatic carcinoma), and FIG. 8e (grade 4 prostatic carcinoma), and are also included in the summarized results shown in TABLE 1. Light to strong staining was observed in the glandular epithelia of all prostate cancer samples tested as well as in all samples derived from normal prostate or benign disease. The signal appears to be strongest at the cell membrane of the epithelial cells, especially at the cell-cell junctions (FIG. 8c, d and e) and is also inhibited with excess STEAP N-terminal peptide 1 (data not shown). Some basal cell staining is also seen in normal prostate (FIG. 8c), which is more apparent when examining atrophic glands (data not shown). STEAP-1 seems to be expressed at all stages of prostate cancer since lower grades (FIG. 8d), higher grades (FIG. 8e) and metastatic prostate cancer (represented by LAPC-9; FIG. 8f) all exhibit strong staining.

Immunohistochemical staining of a large panel of normal non-prostate tissues showed no detectable STEAP-1 expression in 24 of 27 of these normal tissues (Table 1). Only three tissue samples showed some degree of anti-STEAP-1 staining. In particular, normal bladder exhibited low levels of cell surface staining in the transitional epithelium (FIG. 8g). Pancreas and pituitary showed low levels of cytoplasmic staining (Table 1). It is unclear whether the observed cytoplasmic staining is specific or is due to non-specific binding of the antibody, since northern

blotting showed little to no STEAP-1 expression in pancreas (FIG. 3). Normal colon, which exhibited higher mRNA levels than pancreas by Northern blotting (FIG. 3), exhibited no detectable staining with anti-STEAP antibodies (FIG. 8h). These results indicate that cell surface expression of STEAP-1 in normal tissues appears to be restricted to prostate and bladder.

5

TABLE 1: IMMUNOHISTOCHEMICAL STAINING OF HUMAN  
TISSUES WITH ANTI-STEAP-1 POLYCLONAL ANTIBODY

STAINING INTENSITY	TISSUE
NONE	cerebellum, cerebral cortex, spinal cord, heart, skeletal muscle, artery, thymus, spleen, bone marrow, lymph node, lung, colon, liver, stomach, kidney, testis, ovary, fallopian tubes, placenta, uterus, breast, adrenal gland, thyroid gland, skin, bladder (3/5)
LIGHT TO MODERATE	bladder (2/5), pituitary gland (cytoplasmic), pancreas (cytoplasmic), BPH (3/5), prostate cancer (3/10)
STRONG	prostate (2/2), BPH (2/5), prostate cancer** (7/10)

10

15

20

\*In cases where more than one sample is analyzed per tissue, the numbers in brackets indicates how many samples correspond to the staining category/total analyzed.

\*\*Prostate cancer grades ranged from Gleason grades 3 to 5.

25

#### **EXAMPLE 4:**

#### **BIOCHEMICAL CHARACTERIZATION OF STEAP-1 PROTEIN**

To initially characterize the STEAP-1 protein, cDNA clone 10 was cloned into the pcDNA 3.1 Myc-His plasmid (Invitrogen), which encodes a 6His tag at the carboxyl-terminus, transfected into 293T cells, and analyzed by flow cytometry using anti-His monoclonal antibody (His-probe, Santa Cruz) as well as the anti-STEAP-1 polyclonal antibody described above. Staining of cells was performed on intact cells as well as permeabilized cells. The results indicated that only permeabilized cells stained with both antibodies, suggesting that both termini of the STEAP-1 protein are localized intracellularly. It is therefore possible that one or more of the STEAP-1 protein termini are associated with intracellular organelles rather than the plasma membrane.

30

35

To determine whether STEAP-1 protein is expressed at the cell surface, intact STEAP-1-transfected 293T cells were labeled with a biotinylation reagent that does not enter live cells. STEAP-1 was then immunoprecipitated from cell extracts using the anti-His and anti-STEAP antibodies. SV40 large T antigen, an intracellular protein that is expressed at high levels in 293T cells, and the endogenous cell surface transferrin receptor were immunoprecipitated as negative and positive controls, respectively. After immunoprecipitation, the proteins were transferred to a membrane and visualized with horseradish peroxidase-conjugated streptavidin. The results of this analysis are shown in FIG. 7. Only the transferrin receptor (positive control) and STEAP-1 were labeled with biotin, while the SV40 large T antigen (negative control) was not detectably labeled (FIG. 7A). Since only cell surface proteins are labeled with this technique, it is clear from these results that STEAP-1 is a cell surface protein. Combined with the results obtained from the flow cytometric analysis, it is clear that STEAP-1 is a cell surface protein with intracellular amino- and carboxyl- termini.

Furthermore, the above results together with the STEAP-1 secondary structural predictions, shows that STEAP-1 is a type IIIa membrane protein with a molecular topology of six potential transmembrane domains, 3 extracellular loops, 2 intracellular loops and two intracellular termini. A schematic representation of STEAP-1 protein topology relative to the cell membrane is shown in FIG. 1B.

In addition, prostate, bladder and colon cancer cells were directly analyzed for cell surface expression of STEAP-1 by biotinylation studies. Briefly, biotinylated cell surface proteins were affinity purified with streptavidin-gel and probed with the anti-STEAP-1 polyclonal antibody described above. Western blotting of the streptavidin purified proteins clearly show cell surface biotinylation of endogenous STEAP-1 in all prostate (LNCaP, PC-3, DU145), bladder (UM-UC-3, TCCSUP) and colon cancer (LoVo, Colo) cells tested, as well as in NIH 3T3 cells infected with a STEAP-1 encoding retrovirus, but not in non-expressing NIH 3T3 cells used as a negative control (FIG. 7B). In a further negative control, STEAP-1 protein was not detected in streptavidin precipitates from non-biotinylated STEAP expressing cells (FIG. 7B).

#### **EXAMPLE 5:**

##### **IDENTIFICATION AND STRUCTURAL ANALYSIS OTHER HUMAN STEAPS**

STEAP-1 has no homology to any known human genes. In an attempt to identify additional genes that are homologous to STEAP-1, the protein sequence of STEAP-1 was used as an electronic probe to identify family members in the public EST (expression sequence tag) database (dbest). Using the "tblastn" function in NCBI (National Center for Biotechnology Information), the dbest database was queried with the STEAP-1 protein sequence. This analysis

revealed additional putative STEAP-1 homologues or STEAP family members, as further described below.

In addition, SSH cloning experiments also identified a STEAP-1 related cDNA fragment, clone 98P4B6. This clone was isolated from SSH cloning using normal prostate cDNA as tester and LAPC-4 AD cDNA as driver. A larger partial sequence of the 98P4B6 clone was subsequently isolated from a normal prostate library; this clone encodes an ORF of 173 amino acids with close homology to the primary structure of STEAP-1, and thus was designated STEAP-2. A full length STEAP-2 cDNA of 2454 bp was isolated from a prostate library. The STEAP-2 nucleotide and encoded ORF amino acid sequences are shown in FIG. 9. An amino acid alignment of the STEAP-1 and partial STEAP-2 primary structures is shown in FIGS. 11A and 11B. STEAP-1 and – 2 share 61% identity over their 171 amino acid residue overlap (FIG. 11B). The STEAP-2 cDNA has been deposited with the American Type Culture Collection ("ATCC") (Manassas, VA) as plasmid 98P4B6-GTD3 as ATCC Accession Number PTA-311.

The STEAP-2 cDNA (98P4B6-GTD3) contains a 355 bp 5'UTR (untranslated region) that is 72% GC rich, suggesting that it contains translational regulatory elements. The cDNA encodes an open reading frame (ORF) of 454 amino acids (a.a.) with six potential transmembrane domains. This is in contrast to STRAP, which is 339 a.a. in length. Alignment with STRAP-1 demonstrates 54.9% identity over a 237 amino acid overlap. Interestingly, the locations of the six putative transmembrane domains in STRAP-2 coincide with the locations of the transmembrane domains in STRAP-1 (see alignment). The homology of STRAP-2 with STRAP-1 is highest in the regions spanned by the first putative extracellular loop to the fifth transmembrane domain. This analysis and the sequence of STRAP-2 suggest some significant differences between STRAP-1 and STRAP-2: STRAP-2 exhibits a 205 a.a. long intracellular N-terminus (compared to 69 a.a. in STRAP-1) and a short 4 a.a. intracellular C-terminus (compared to 26 a.a. in STRAP-1). These differences could imply significant differences in function and/or interaction with intracellular signaling pathways. To identify a unique mouse EST corresponding to STRAP-2, the unique N-terminus of STRAP-2 was used to query the dbest database. One mouse EST was isolated (AI747886, mouse kidney) that may be used in the identification of mouse STRAP-2 and in expression analysis of STRAP-2 in mouse.

Two ESTs encoding ORFs bearing close homology to the STEAP-1 and STEAP-2 sequences were also identified by electronic probing with the STEAP-1 protein sequence. These ESTs (AI139607 and R80991) were provisionally designated STEAP-3 and STEAP-4. A full length cDNA encoding STEAP-3 was subsequently cloned, and its nucleotide and deduced amino acid sequences are shown in FIG. 10A. The nucleotide sequences of the ESTs corresponding to the STEAPs are reproduced in FIG. 10B.

An amino acid alignment of the structures of STEAP-1, STEAP-2, STEAP-3 and the partial sequence of the putative STEAP-4 is shown in FIG. 11A. This alignment shows a close structural similarity between all four STEAP family proteins, particularly in the predicted transmembrane domains. As indicated above, STEAP-1 and STEAP-2 demonstrate 54.9% identity over a 237 amino acid overlap. STEAP-1 and STEAP-3 are 40.9% identical over a 264 amino acid region, while STEAP-2 and STEAP-3 are 47.8% identical over a 416 amino acid region.

#### **EXAMPLE 6:**

##### **EXPRESSION ANALYSIS OF STEAP-2 AND OTHER HUMAN STEAP FAMILY MEMBERS**

##### **Example 6A: Tissue Specific Expression of STEAP Family Members in Normal Human Tissues**

RT-PCR analysis of STEAP-2 shows expression in all the LAPC prostate cancer xenografts and in normal prostate (FIG. 14, panel A). Analysis of 8 normal human tissues shows prostate-specific expression after 25 cycles of amplification (FIG. 14, panel B). Lower level expression in other tissues was detected only after 30 cycles of amplification. Northern blotting for STEAP-2 shows a pattern of 2 transcripts (approximately 3 and 8 kb in size) expressed only in prostate (and at significantly lower levels in the LAPC xenografts), with no detectable expression in any of the 15 other normal human tissues analyzed (FIG. 15, panel C). Thus, STEAP-2 expression in normal human tissues appears to be highly prostate-specific.

Expression analysis of STEAP family members in normal tissues was performed by Northern blot and/or RT-PCR. All STEAP family members appeared to exhibit tissue restricted expression patterns. STEAP-3/AI139607 expression is shown in FIG. 12A (Northern) and FIG. 12B (RT-PCR). STEAP-4/R80991 expression is shown in FIG. 13.

##### **Example 6B: Expression of STEAP-2 in Various Cancer Cell Lines**

The RT-PCR results above suggested that the different STEAP family members exhibit different tissue expression patterns. Interestingly, STEAP-2, which appears very prostate-specific, seems to be expressed at lower levels in the LAPC xenografts. This is in contrast to STEAP-1, which is highly expressed in both normal and malignant prostate tissue.

To better characterize this suggested difference in the STEAP-2 prostate cancer expression profile (relative to STEAP-1), Northern blotting was performed on RNA derived from the LAPC xenografts, as well as several prostate and other cancer cell lines, using a STEAP-2 specific probe (labeled cDNA clone 98P4B6). The results are shown in FIG. 16 and can be summarized as







susceptible to aggressive prostate cancer, as well as other types of cancer, particularly colon, bladder, pancreatic, ovarian, cervical and testicular cancers.

Southern blot analysis shows that the STEAP-1 gene exists in several species including mouse (FIG. 19). Therefore, a mouse BAC library (Mouse ES 129-V release I, Genome Systems, FRAC-4431) was screened with the human cDNA for STEAP-1 (clone 10, Example 2). One positive clone, 12P11, was identified and confirmed by southern blotting (FIG. 20). The intron-exon boundary information for human STEAP may be used to identify the mouse STEAP-1 coding sequences.

The mouse STEAP-1 genomic clone may be used to study the biological role of STEAP-1 during development and tumorigenesis. Specifically, the mouse genomic STEAP-1 clone may be inserted into a gene knock-out (K/O) vector for targeted disruption of the gene in mice, using methods generally known in the art. In addition, the role of STEAP in metabolic processes and epithelial cell function may be elucidated. Such K/O mice may be crossed with other prostate cancer mouse models, such as the TRAMP model (Greenberg et al., 1995, PNAS 92:3439), to determine whether STEAP influences the development and progression of more or less aggressive and metastatic prostate cancers.

#### **EXAMPLE 9:**

##### **PREDICTION OF HLA-A2 BINDING PEPTIDES FROM STEAP-1 AND STEAP-2**

The complete amino acid sequences of the STEAP-1 and STEAP-2 proteins were entered into the HLA Peptide Motif Search algorithm found in the Bioinformatics and Molecular Analysis Section (BIMAS) Web site (<http://bimas.dcrf.nih.gov/>). The HLA Peptide Motif Search algorithm was developed by Dr. Ken Parker based on binding of specific peptide sequences in the groove of HLA Class I molecules and specifically HLA-A2 (Falk et al., 1991, Nature 351: 290-6; Hunt et al., 1992, Science 255:1261-3; Parker et al., 1992, J. Immunol. 149:3580-7; Parker et al., 1994, J. Immunol. 152:163-75). This algorithm allows location and ranking of 8-mer, 9-mer, and 10-mer peptides from a complete protein sequence for predicted binding to HLA-A2 as well as other HLA Class I molecules. Most HLA-A2 binding peptides are 9-mers favorably containing a leucine (L) at position 2 and a valine (V) or leucine (L) at position 9.

The results of STEAP-1 and STEAP-2 predicted binding peptides are shown in Table 2 below. For both proteins the top 5 ranking candidates are shown along with their location, the amino acid sequence of each specific peptide, and an estimated binding score. The binding score corresponds to the estimated half-time of dissociation of complexes containing the peptide at 37°C at pH 6.5. Peptides with the highest binding score (i.e. 10776.470 for STEAP-1 peptide 165; 1789.612 for STEAP-2 peptide 227) are predicted to be the most tightly bound to HLA Class I on the cell surface and thus represent the best immunogenic targets for

T-cell recognition. Actual binding of peptides to HLA-A2 can be evaluated by stabilization of HLA-A2 expression on the antigen-processing defective cell line T2 (Refs. 5,6). Immunogenicity of specific peptides can be evaluated in vitro by stimulation of CD8+ cytotoxic T lymphocytes (CTL) in the presence of dendritic cells (Xue et al., 1997, Prostate 30:73-8; Peshwa et al., 1998, Prostate 36:129-38).

**Table 1: Predicted Binding of STEAP-1 and STEAP-2 Peptide Sequences with Highest Affinity for HLA-A2**

STEAP-1			
Rank	Start Position	Subsequence Residue Listing	Score (Estimate of Half Time of Disassociation of Molecule containing This Subsequence)
1	165	GLLSFFFAV	10776.470
2	86	FLYTLLREV	470.951
3	262	LLLGTIHAL	309.050
4	302	LIFKSILFL	233.719
5	158	MLTRKQFGL	210.633

STEAP-2			
Rank	Start Position	Subsequence Residue Listing	Score (Estimate of Half Time of Disassociation of Molecule containing This Subsequence)
1	227	FLYSFVRDV	1789.612
2	402	ALLISTFHV	1492.586
3	307	LLSFFFAMV	853.681
4	306	GLLSFFFAM	769.748
5	100	SLWDLRHLL	726.962

June 1, 1999, entitled "NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS AND USES THEREOF" The proteins designated "STRAP" in that application have been re-named "STEAP" in the present application.

- 5 Throughout this application, various publications are referenced within parentheses. The disclosures of these publications are hereby incorporated by reference herein in their entireties.

The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any which are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing from the true scope and spirit of the invention.

15

## **CLAIMS:**

1. An isolated STEAP-2 protein having an amino acid sequence shown in FIG. 9.
- 5 2. An isolated polypeptide of at least 8 contiguous amino acids of the protein of claim 1.
3. An isolated polypeptide comprising an amino acid sequence which is at least 90% identical to the amino acid sequence shown in FIG. 9 over its entire length.
- 10 4. An isolated polynucleotide selected from the group consisting of (a) a polynucleotide having the sequence as shown in FIG. 9, wherein T can also be U; (b) a polynucleotide encoding a STEAP-2 polypeptide whose sequence is encoded by the cDNA contained in plasmid 98P4B6-GTD3 as deposited with American Type Culture Collection as Accession No. PTA-311; and (c) a polynucleotide encoding the STEAP-2 protein of claim 1.
- 15 5. An isolated polynucleotide which selectively hybridizes under stringent conditions to a polynucleotide according to claim 4 or its complement.
6. An isolated fragment of a polynucleotide according to claim 4 which is at least 20  
20 nucleotide bases in length.
7. An isolated polynucleotide which is fully complementary to a polynucleotide according to claim 4.
- 25 8. An isolated fragment of a polynucleotide according to claim 7 which is at least 20 nucleotide bases in length.
9. A recombinant expression vector which contains a polynucleotide according to claim 4.
- 30 10. A host cell which contains an expression vector according to claim 9.
11. An isolated polynucleotide according to claim 5 which is labeled with a detectable marker.
12. A process for producing a STEAP-2 protein comprising culturing a host cell of claim 10  
35 under conditions sufficient for the production of the polypeptide and recovering the STEAP-2 protein from the culture.
13. An antibody which specifically binds to the STEAP-2 protein of claim 1.

14. A monoclonal antibody according to claim 13.
15. The monoclonal antibody of claim 14 which is labeled with a detectable marker.
- 5 16. The monoclonal antibody of claim 14 which is conjugated to a toxin.
17. The monoclonal antibody of claim 14 which is conjugated to a therapeutic agent.
- 10 18. An assay for detecting the presence of a STEAP-2 protein in a biological sample comprising contacting the sample with an antibody of claim 15, and detecting the binding of STEAP-2 protein in the sample thereto.
- 15 19. An assay for detecting the presence of a STEAP-2 polynucleotide in a biological sample, comprising
  - (a) contacting the sample with a polynucleotide probe which specifically hybridizes to a polynucleotide of claim 4 or its complement; and
  - 20 (b) detecting the presence of a hybridization complex formed by the hybridization of the probe with STEAP-2 polynucleotide in the sample, wherein the presence of the hybridization complex indicates the presence of STEAP-2 polynucleotide within the sample.
- 25 20. An assay for detecting the presence of STEAP-2 mRNA in a biological sample comprising:
  - (a) producing cDNA from the sample by reverse transcription using at least one primer;
  - (b) amplifying the cDNA so produced using STEAP-2 polynucleotides as sense and antisense primers to amplify STEAP-2 cDNAs therein;
  - 30 (c) detecting the presence of the amplified STEAP-2 cDNA,wherein the STEAP-2 polynucleotides used as the sense and antisense primers are capable of amplifying the polynucleotide shown in FIG. 9.
- 35 21. A composition for the treatment of prostate cancer comprising an antibody according to claim 14, 16 or 17, wherein the antibody binds to an extracellular domain of STEAP-2.

22. A vaccine composition for the treatment of a cancer expressing a STEAP-2 protein comprising a STEAP-2 protein according to claim 1 and a physiologically acceptable carrier.
23. A vaccine composition for the treatment of a cancer expressing a STEAP-2 protein comprising an immunogenic portion of a STEAP-2 protein according to claim 2 and a physiologically acceptable carrier.
24. An isolated STEAP-3 protein having an amino acid sequence shown in FIG. 10A.
25. An isolated polypeptide of at least 8 contiguous amino acids of the protein of claim 24.
26. An isolated polypeptide comprising an amino acid sequence which is at least 90% identical to the amino acid sequence shown in FIG. 10A over its entire length.
27. An isolated polynucleotide selected from the group consisting of (a) a polynucleotide having the sequence as shown in FIG. 10A, wherein T can also be U; and (b) a polynucleotide encoding the STEAP-3 protein of claim 1.
28. An isolated polynucleotide which selectively hybridizes under stringent conditions to a polynucleotide according to claim 27 or its complement.
29. An antibody which specifically binds to the STEAP-3 protein of claim 24.
30. A monoclonal antibody according to claim 24.
31. The monoclonal antibody of claim 30 which is labeled with a detectable marker.
32. The monoclonal antibody of claim 30 which is conjugated to a toxin.
33. The monoclonal antibody of claim 30 which is conjugated to a therapeutic agent.
34. An assay for detecting the presence of a STEAP-3 protein in a biological sample comprising contacting the sample with an antibody of claim 31, and detecting the binding of STEAP-3 protein in the sample thereto.
35. An assay for detecting the presence of a STEAP-3 polynucleotide in a biological sample, comprising

- (a) contacting the sample with a polynucleotide probe which specifically hybridizes to a polynucleotide of claim 27 or its complement; and
- (b) detecting the presence of a hybridization complex formed by the hybridization of the probe with STEAP-3 polynucleotide in the sample, wherein the presence of the hybridization complex indicates the presence of STEAP-3 polynucleotide within the sample.
36. An assay for detecting the presence of STEAP-3 mRNA in a biological sample comprising:
- (a) producing cDNA from the sample by reverse transcription using at least one primer;
- (b) amplifying the cDNA so produced using STEAP-3 polynucleotides as sense and antisense primers to amplify STEAP-3 cDNAs therein;
- (c) detecting the presence of the amplified STEAP-3 cDNA,
- wherein the STEAP-3 polynucleotides used as the sense and antisense primers are capable of amplifying the polynucleotide shown in FIG. 10A.
37. A composition for the treatment of prostate cancer comprising an antibody according to claim 30, 32 or 33, wherein the antibody binds to an extracellular domain of STEAP-3.
38. A vaccine composition for the treatment of a cancer expressing a STEAP-3 protein comprising a STEAP-3 protein according to claim 24 and a physiologically acceptable carrier.
39. A vaccine composition for the treatment of a cancer expressing a STEAP-3 protein comprising an immunogenic portion of a STEAP-3 protein according to claim 25 and a physiologically acceptable carrier.
40. A method of inhibiting the growth of tumor cells expressing a STEAP-2 protein, comprising administering to a patient an antibody which binds specifically to the extracellular domain of STEAP-2 in an amount effective to inhibit growth of the tumor cells.
41. The method of claim 40, wherein said antibody is conjugated to a cytotoxic agent.



42. A method of treating a patient susceptible to or having a cancer which expresses STEAP-2, comprising administering to said patient an effective amount of an antibody which binds specifically to the extracellular domain of STEAP-2.

5 43. The method of claim 42 wherein said antibody is conjugated to a cytotoxic agent.

## **ABSTRACT**

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed "STEAP" (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C- termini, suggesting that it folds in a "serpentine" manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

## FIG. 1A


5'	11				20				29				38				47				56			
	GAG	ACT	CAC	GGT	CAA	GCT	AAG	GCG	AAG	AGT	GGG	TGG	CTG	AAG	CCA	TAC	TAT	TTT						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	65				74				83				92				101				110			
	ATA	GAA	TTA	<b>ATG</b>	GAA	AGC	AGA	AAA	GAC	ATC	ACA	AAC	CAA	GAA	GAA	CTT	TGG	AAA						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
				<b>M</b>	<b>E</b>	<b>S</b>	<b>R</b>	<b>K</b>	<b>D</b>	<b>I</b>	<b>T</b>	<b>N</b>	<b>Q</b>	<b>E</b>	<b>E</b>	<b>L</b>	<b>W</b>	<b>K</b>						
	119				128				137				146				155				164			
	ATG	AAG	CCT	AGG	AGA	AAT	TTA	GAA	GAA	GAC	GAT	TAT	TTG	CAT	AAG	GAC	ACG	GGA						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>M</b>	<b>K</b>	<b>P</b>	<b>R</b>	<b>R</b>	<b>N</b>	<b>L</b>	<b>E</b>	<b>E</b>	<b>D</b>	<b>D</b>	<b>Y</b>	<b>L</b>	<b>H</b>	<b>K</b>	<b>D</b>	<b>T</b>	<b>G</b>						
	173				182				191				200				209				218			
	GAG	ACC	AGC	ATG	CTA	AAA	AGA	CCT	GTG	CTT	TTG	CAT	TTG	CAC	CAA	ACA	GCC	CAT						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>E</b>	<b>T</b>	<b>S</b>	<b>M</b>	<b>L</b>	<b>K</b>	<b>R</b>	<b>P</b>	<b>V</b>	<b>L</b>	<b>L</b>	<b>H</b>	<b>L</b>	<b>H</b>	<b>Q</b>	<b>T</b>	<b>A</b>	<b>H</b>						
	227				236				245				254				263				272			
	GCT	GAT	GAA	TTT	GAC	TGC	CCT	TCA	GAA	CTT	CAG	CAC	ACA	CAG	GAA	CTC	TTT	CCA						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>A</b>	<b>D</b>	<b>E</b>	<b>F</b>	<b>D</b>	<b>C</b>	<b>P</b>	<b>S</b>	<b>E</b>	<b>L</b>	<b>Q</b>	<b>H</b>	<b>T</b>	<b>Q</b>	<b>E</b>	<b>L</b>	<b>F</b>	<b>P</b>						
	281				290				299				308				317				326			
	CAG	TGG	CAC	TTG	CCA	ATT	AAA	ATA	GCT	GCT	ATT	ATA	GCA	TCT	CTG	ACT	TTT	CTT						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>Q</b>	<b>W</b>	<b>H</b>	<b>L</b>	<b>P</b>	<b>I</b>	<b>K</b>	<b>I</b>	<b>A</b>	<b>A</b>	<b>I</b>	<b>I</b>	<b>A</b>	<b>S</b>	<b>L</b>	<b>T</b>	<b>F</b>	<b>L</b>						
	335				344				353				362				371				380			
	TAC	ACT	CTT	CTG	AGG	GAA	GTA	ATT	CAC	CCT	TTA	GCA	ACT	TCC	CAT	CAA	CAA	TAT						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>Y</b>	<b>T</b>	<b>L</b>	<b>L</b>	<b>R</b>	<b>E</b>	<b>V</b>	<b>I</b>	<b>H</b>	<b>P</b>	<b>L</b>	<b>A</b>	<b>T</b>	<b>S</b>	<b>H</b>	<b>Q</b>	<b>Q</b>	<b>Y</b>						
	389				398				407				416				425				434			
	TTT	TAT	AAA	ATT	CCA	ATC	CTG	GTC	ATC	AAC	AAA	GTC	TTG	CCA	ATG	GTT	TCC	ATC						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>F</b>	<b>Y</b>	<b>K</b>	<b>I</b>	<b>P</b>	<b>I</b>	<b>L</b>	<b>V</b>	<b>I</b>	<b>N</b>	<b>K</b>	<b>V</b>	<b>L</b>	<b>P</b>	<b>M</b>	<b>V</b>	<b>S</b>	<b>I</b>						
	443				452				461				470				479				488			
	ACT	CTC	TTG	GCA	TTG	GTT	TAC	CTG	CCA	GGT	GTG	ATA	GCA	GCA	ATT	GTC	CAA	CTT						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>T</b>	<b>L</b>	<b>L</b>	<b>A</b>	<b>L</b>	<b>V</b>	<b>Y</b>	<b>L</b>	<b>P</b>	<b>G</b>	<b>V</b>	<b>I</b>	<b>A</b>	<b>A</b>	<b>I</b>	<b>V</b>	<b>Q</b>	<b>L</b>						
	497				506				515				524				533				542			
	CAT	AAT	GGA	ACC	AAG	TAT	AAG	AAG	TTT	CCA	CAT	TGG	TTG	GAT	AAG	TGG	ATG	TTA						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>H</b>	<b>N</b>	<b>G</b>	<b>T</b>	<b>K</b>	<b>Y</b>	<b>K</b>	<b>K</b>	<b>F</b>	<b>P</b>	<b>H</b>	<b>W</b>	<b>L</b>	<b>D</b>	<b>K</b>	<b>W</b>	<b>M</b>	<b>L</b>						
	551				560				569				578				587				596			
	ACA	AGA	AAG	CAG	TTT	GGG	CTT	CTC	AGT	TTC	TTT	TTT	GCT	GTA	CTG	CAT	GCA	ATT						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>T</b>	<b>R</b>	<b>K</b>	<b>Q</b>	<b>F</b>	<b>G</b>	<b>L</b>	<b>L</b>	<b>S</b>	<b>F</b>	<b>F</b>	<b>F</b>	<b>A</b>	<b>V</b>	<b>L</b>	<b>H</b>	<b>A</b>	<b>I</b>						
	605				614				623				632				641				650			
	TAT	AGT	CTG	TCT	TAC	CCA	ATG	AGG	CGA	TCC	TAC	AGA	TAC	AAG	TTG	CTA	AAC	TGG						
	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---						
	<b>Y</b>	<b>S</b>	<b>L</b>	<b>S</b>	<b>Y</b>	<b>P</b>	<b>M</b>	<b>R</b>	<b>R</b>	<b>S</b>	<b>Y</b>	<b>R</b>	<b>Y</b>	<b>K</b>	<b>L</b>	<b>L</b>	<b>N</b>	<b>W</b>						

659	668	677	686	695	704
GCA TAT CAA CAG GTC	CAA CAA AAT AAA	GAA GAT GCC TGG	ATT GAG CAT GAT	GTT	
A Y Q Q V	Q Q N K E	D A W I E	H D V		
713	722	731	740	749	758
TGG AGA ATG GAG ATT	TAT GTG TCT CTG	GGA ATT GTG GGA	TTG GCA ATA CTG	GCT	
W R M E I	<u>Y V S L G I V G L A I L A</u>				
767	776	785	794	803	812
CTG TTG GCT GTG ACA	TCT ATT CCA TCT	GTG AGT GAC TCT	TTG ACA TGG	AGA GAA	
<u>L L A V T S I P S V</u>	S D S L T W R E				
821	830	839	848	857	866
TTT CAC TAT ATT CAG	AGC AAG CTA GGA	ATT GTT TCC CTT	CTA CTG GGC	ACA ATA	
F H Y I	<u>Q S K L G I V S L L L G T I</u>				
875	884	893	902	911	920
CAC GCA TTG ATT TTT	GCC TGG AAT AAG	TGG ATA GAT ATA	AAA CAA TTT	GTA TGG	
<u>H A L I F A W N K</u>	W I D I K Q F V W				
929	938	947	956	965	974
TAT ACA CCT CCA ACT	TTT ATG ATA GCT	GTT TTC CTT CCA	ATT GTT GTC	CTG ATA	
Y T P P T F	<u>M I A V F L P I V V L I</u>				
983	992	1001	1010	1019	1028
TTT AAA AGC ATA CTA	TTC CTG CCA TGC	TTG AGG AAG AAG	ATA CTG AAG	ATT AGA	
<u>F K S I L F L P C L</u>	R K K I L K I R				
1037	1046	1055	1064	1073	1082
CAT GGT TGG GAA GAC	GTC ACC AAA ATT	AAC AAA ACT GAG	ATA TGT TCC	CAG TTG	
H G W E D V T	K I N K T E I C S Q L				
1091	1100	1109	1118	1127	1136
TAG AAT TAC TGT TTA	CAC ACA TTT TTG	TTC AAT ATT GAT	ATA TTT TAT	CAC CAA	
* N Y C L H T F L F	N I D I F Y H Q				
1145	1154	1163	1172	1181	1190
CAT TTC AAG TTT GTA	TTT GTT AAT AAA	ATG ATT ATT CAA	GGA AAA AAA	AAA AAA	
H F K F V F V N K M I I	Q G K K K K				

AAA AA 3'

K


FIG. 1B



# FIG. 1C

5' GGC GGA GGC GGA GGC GGA GGG CGA GGG GCG GGG AGC GCC GCC TGG AGC GCG  
GCA GGT CAT ATT GAA CAT TCC AGA TAC CTA TCA TTA CTC GAT GCT GTT GAT  
AAC AGC AAG 3'

**FIG. 2**



**Panels:**

**A**

1. Brain
2. Prostate
3. LAPC-4 AD
4. LAPC-4 AI
5. LAPC-9 AD
6. HeLa
7. Murine cDNA
8. Neg. control

**B**

1. Brain
2. Heart
3. Kidney
4. Liver
5. Lung
6. Pancreas
7. Placenta
8. Skeletal Muscle

**C**

1. Colon
2. Ovary
3. Leukocytes
4. Prostate
5. Small Intestine
6. Spleen
7. Testis
8. Thymus

FIG. 3A







FIG. 3B



## FIG. 4

GGGGCCCGCACCTCTGGGCAGCAGCGGCAGCCGAGACTCACGGTCAAGCTAAGGCGAAGAGTGGGTGGCTGAAGCC  
ATACTATTTTATAGAATTAATGGAAAGCAGAAAAGACATCACAAACCAAGAAGAACTTTGGAAAATGAAGCCTAGG  
AGAAAATTTAGAAGAAGACGATTATTTGCATAAGGACACGGGAGAGACCAGCATGCTAAAAAGACCTGTGCTTTTGC  
ATTTGCACCAAACAGCCCATGCTGATGAATTTGACTGCCCTTCAGAACTTCAGCACACACAGGAACCTCTTTCCACA  
GTGGCACTTGCCAATTAATAAGCTGCTATTATAGCATCTCTGACTTTTCTTTTACACTCTTCTGAGGGAAGTAATT  
CACCCCTTAGCAACTTCCCATCAACAATATTTTATAAAATTCCAATCCTGGTCATCAACAAAGTCTTGCCAATGG  
TTTCCATCACTCTCTTGGCATTGGTTTACCTGCCAGGTGTGATAGCAGCAATTGTCCAACCTTCATAATGGAACCAA  
GTATAAGAAGTTTCCACATTGGTTGGATAAGTGGATGTTAACAAGAAAGCAGTTTGGGCTTCTCAGTTTCTTTTTT  
GCTGTACTGCATGCAATTTATAGTCTGTCTTACCCAATGAGGCGATCCTACAGATACAAGTTGCTAAACTGGGCAT  
ATCAACAGGTCCAACAAAATAAGAAGATGCCGGATTGAGCATGATGTTGGAGAATGGAGATTTATGTGTCTCT  
GGGAATTGTGGGATTGGCAATACTGGCTCTGTTGGCTGTGACATCTATTCCATCTGTGAGTGAACCTTTGACATGG  
AGAGAATTTCACTATATTCAGGTAAATAATATATAAAATAACCCTAAGAGGTAAATCTTCTTTTTGTGTTTATGAT  
ATAGAATATGTTGACTTTACCCCATAAAAATAACAAATGTTTTTCAACAGCAAAGATCTTATACTTGTTCCAATT  
AATAATGTGCTCTCCTGTTGTTTTCCCTATTGCTTCTAATTAGGACAAGTGTTCCTAGACATAAATAAAGGCAT  
TAAAATATTCTTTGTTTTTTTTTTTTTTGTTTGTGTTTTTTGTTTGTGTTTGTGTTTTTTGAGATGAAGTCTCG  
CTCTGTTGCCCATGCTGGAGTACAGTGGCACGATCTCGGCTCACTGCAACCTGCGCCTCCTGGGTTCAAGCGATT  
TCTTGCCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCACCCATCACCATGTCCAGCTAATTTTTGTATTTTTAGTA  
GAGACAGGGTTTTCCCATGTTGGCCAGGCTGGTCTCGATCTCCTGACCTCAAATGATCCGCCACCTCGGCCTCCC  
AAAGTGCTGGGATGACAGTTGTGAGCCACCACACTCAGCCTGCTCTTTCTAATATTTGAAACTTGTTAGACAATTT  
GCTACCCATCTAATGTGATATTTTAGGAATCCAATATGCATGGTTTATTATTTCTTAAAAAAATATTCTTTTACC  
TGTACCTGAATTTAGTAATGCCTTTTATGTTACACAACCTTAGCACTTTCCAGAAACAAAACCTCTCTCCTTGAAA  
TAATAGAGTTTTTATCTACCAAAGATATGCTAGTGTCTCATTTCAAAGGCTGCTTTTTCCAGCTTACATTTTATAT  
ACTTACTCACTTGAAGTTTCTAAATATCTTGTAATTTTAAACTATCTCAGATTTACTGAGGTTTATCTTCTGGT  
GGTAGATTATCCATAAGAAGAGTGATGTGCCAGAATCACTCTGGGATCCTTGTCTGACAAGATTCAAAGGACTAAA  
TTTAATTCAGTCATGAACACTGCCAATTACCGTTTATGGGTAGACATCTTTGGAAATTTCCACAAGGTGAGACATT  
CGCAACTATCCCTTCTACATGTCCACACGTATACTCCAACACTTTATTAGGCATCTGATTAGTTTGGAAAGTATGC  
CTCCATCTGAATTAGTCCAGTGTGGCTTAGAGTTGGTACAACATTCTCACAGAATTCCTAATTTTGTAGGTTGAG  
CCTGATAACCACTGGAGTTCTTTGGTCCTATTAAATAGCTTTCTTCACACATTGCTCTGCTGTACACATATGA  
TGAACACTGCTTTTTAGACTTCATTAGGAATTTAGGACTGCATCTTGACAACCTGAGCCTATTCTACTATATGTACA

ATACCTAGCCCATAATAGGTATACAATACACATTTGGTAAACTAATTTTCAACCAATGACATGTATTTTCAACT  
AGTAACCTAGAAATGTTTCACTTAAAATCTGAGAACTGGTTACACTACAAGTTACCTTGGAGATTCATATATGAAA  
ACGCAAACTTAGCTATTTGATTGTATTCCTGGGACTTAAGAATGCGCCTGAATAATTGTGAGTTCGATTTGTTCT  
GGCAGGCTAATGACCATTTCCAGTAAAGTGAATAGAGGTGAGAAGTCGTATAAAAGAGGTGTTGTGAGAACCCGT  
TGAGATTACATAGGTGAACAACCTATTTTAAAGCAACTTTATTTGTGTAGTGACAAAGCATCCCAATGCAGGCTGAA  
ATGTTTCATCACATCTCTGGATCTCTCTATTTTGTGCAGACATTGAAAAAATTGTTTCATATTATTTCCATGTATC  
AGAATATTTGATTTTAAAAACATAGGCCAAGTTCATTCACCTCATTATTCATTTATCAAAATCAGAGTGAATCA  
CATTAGTCGCCTTCACAACTGATAAAGATCACTGAAGTCAAATTGATTTTGTCTATAATCTTCAATCTACCTATAT  
TTAATTGAGAATCTAAAATGTACAAATCATTGTGTTGATTCTGCAGTGATCCTGCTATAAGTAAGACTCAGTCCCT  
GATTTTAGGTATCCTGTGAAAAGCAGAATTAAGACAAATACACAAGAGACAAAGCACAAAAATAAATATCATAAG  
GGGATGAACAAAATGGTGGAGAAAGAGTAGACAAAGTTTTTGATCACCTGCCTTCAAAGAAAGGCTGTGAATTTTG  
TTCACCTAGACAGCTTGGAGACAAGAAATTACCCAAAAGTAAGGTGAGGAGGATAGGCAAAAAGAGCAGAAAGATG  
TGAATGGACATTGTTGAGAAATGTGATAGGAAAACAATCATAGATAAAGGATTTCCAAGCAACAGAGCATATCCAG  
ATGAGGTAGGATGGGATAAACTCTTATTGAACCAATCTTCACCAATTTTGTTCCTTTTGCAGAGCAAGCTAGGA  
**ATTGTTTCCCTTCTACTGGGCACAATACACGCATTGATTTTGCCTGGAATAAGTGGATAGATATAAAACAATTTG**  
**TATGGTATACACCTCCAACCTTTTATGATAGCTGTTTTCTTCCAATTGTTGTCCTGATATTTAAAGCATACTATT**  
**CCTGCCATGCTTGAGGAAGAAGATACTGAAGATTAGACATGGTTGGGAAGACGTCACCAAAATTAACAAAACCTGAG**  
**ATATGTTCCCAGTTGTAG**AATTACTGTTTACACACATTTTGTTCATATTTGATATATTTTATCACCAACATTTCA  
AGTTTGTATTTGTTAATAAAATGATTATTCAAGGAAAAAAAAAAAAAAAAAAAAA

# FIG. 5







FIG. 6



# FIG. 7

**A**



**B**




FIG. 8




FIG. 9

5'	10				19				28				37				46				55	
	GGA	CGC	GTG	GGC	GGA	CGC	GTG	GGT	TCC	TCG	GGC	CCT	CGG	CGC	CAC	AAG	CTG	TCC				
	64				73				82				91				100				109	
	GGG	CAC	GCA	GCC	CCT	AGC	GGC	GCG	TCG	CTG	CCA	AGC	CGG	CCT	CCG	CGC	GCC	TCC				
	118				127				136				145				154				163	
	CTC	CTT	CCT	TCT	CCC	CTG	GCT	GTT	CGC	GAT	CCA	GCT	TGG	GTA	GGC	GGG	GAA	GCA				
	172				181				190				199				208				217	
	GCT	GGA	GTG	CGA	CCG	CCA	CGG	CAG	CCA	CCC	TGC	AAC	CGC	CAG	TCG	GAG	GTG	CAG				
	226				235				244				253				262				271	
	TCC	GTA	GGC	CCT	GGC	CCC	CGG	GTG	GGC	CCT	TGG	GGA	GTC	GGC	GCC	GCT	CCC	GAG				
	280				289				298				307				316				325	
	GAG	CTG	CAA	GGC	TCG	CCC	CTG	CCC	GGC	GTG	GAG	GGC	GCG	GGG	GGC	GCG	GAG	GAT				
	334				343				352				361				370				379	
	ATT	CTT	GGT	GAT	CTT	GGA	AGT	GTC	CGT	<b>ATC</b>	<b>ATG</b>	<b>GAA</b>	TCA	ATC	TCT	ATG	ATG	GGA				
											<b>M</b>	<b>E</b>	<b>S</b>	<b>I</b>	<b>S</b>	<b>M</b>	<b>M</b>	<b>G</b>				
	388				397				406				415				424				433	
	AGC	CCT	AAG	AGC	CTT	AGT	GAA	ACT	TGT	TTA	CCT	AAT	GGC	ATA	AAT	GGT	ATC	AAA				
	S	P	K	S	L	S	E	T	C	L	P	N	G	I	N	G	I	K				
	442				451				460				469				478				487	
	GAT	GCA	AGG	AAG	GTC	ACT	GTA	GGT	GTG	ATT	GGA	AGT	GGA	GAT	TTT	GCC	AAA	TCC				
	D	A	R	K	V	T	V	G	V	I	G	S	G	D	F	A	K	S				
	496				505				514				523				532				541	
	TTG	ACC	ATT	CGA	CTT	ATT	AGA	TGC	GGC	TAT	CAT	GTG	GTC	ATA	GGA	AGT	AGA	AAT				
	L	T	I	R	L	I	R	C	G	Y	H	V	V	I	G	S	R	N				
	550				559				568				577				586				595	
	CCT	AAG	TTT	GCT	TCT	GAA	TTT	TTT	CCT	CAT	GTG	GTA	GAT	GTC	ACT	CAT	CAT	GAA				
	P	K	F	A	S	E	F	F	P	H	V	V	D	V	T	H	H	E				
	604				613				622				631				640				649	
	GAT	GCT	CTC	ACA	AAA	ACA	AAT	ATA	ATA	TTT	GTT	GCT	ATA	CAC	AGA	GAA	CAT	TAT				
	D	A	L	T	K	T	N	I	I	F	V	A	I	H	R	E	H	Y				
	658				667				676				685				694				703	
	ACC	TCC	CTG	TGG	GAC	CTG	AGA	CAT	CTG	CTT	GTG	GGT	AAA	ATC	CTG	ATT	GAT	GTG				
	T	S	L	W	D	L	R	H	L	L	V	G	K	I	L	I	D	V				
	712				721				730				739				748				757	
	AGC	AAT	AAC	ATG	AGG	ATA	AAC	CAG	TAC	CCA	GAA	TCC	AAT	GCT	GAA	TAT	TTG	GCT				
	S	N	N	M	R	I	N	Q	Y	P	E	S	N	A	E	Y	L	A				



766	775	784	793	802	811
TCA TTA TTC CCA GAT TCT TTG ATT GTC AAA GGA TTT AAT GTT GTC TCA GCT TGG					
S L F P D S L I V K G F N V V S A W					
820	829	838	847	856	865
GCA CTT CAG TTA GGA CCT AAG GAT GCC AGC CGG CAG GTT TAT ATA TGC AGC AAC					
A L Q L G P K D A S R Q V Y I C S N					
874	883	892	901	910	919
AAT ATT CAA GCG CGA CAA CAG GTT ATT GAA CTT GCC CGC CAG TTG AAT TTC ATT					
N I Q A R Q Q V I E L A R Q L N F I					
928	937	946	955	964	973
CCC ATT GAC TTG GGA TCC TTA TCA TCA GCC AGA GAG ATT GAA AAT TTA CCC CTA					
P I D L G S L S S A R E I E N L P <u>L</u>					
982	991	1000	1009	1018	1027
CGA CTC TTT ACT CTC TGG AGA GGG CCA GTG GTG GTA GCT ATA AGC TTG GCC ACA					
<u>R L F T L W R G P V V V A I S L A T</u>					
1036	1045	1054	1063	1072	1081
TTT TTT TTC CTT TAT TCC TTT GTC AGA GAT GTG ATT CAT CCA TAT GCT AGA AAC					
<u>F F F L</u> Y S F V R D V I H P Y A R N					
1090	1099	1108	1117	1126	1135
CAA CAG AGT GAC TTT TAC AAA ATT CCT ATA GAG ATT GTG AAT AAA ACC TTA CCT					
Q Q S D F Y K I P I E I <u>V N K T L P</u>					
1144	1153	1162	1171	1180	1189
ATA GTT GCC ATT ACT TTG CTC TCC CTA GTA TAC CTT GCA GGT CTT CTG GCA GCT					
<u>I V A I T L L S L V Y L A G L L A</u> A					
1198	1207	1216	1225	1234	1243
GCT TAT CAA CTT TAT TAC GGC ACC AAG TAT AGG AGA TTT CCA CCT TGG TTG GAA					
A Y Q L Y Y G T K Y R R F P P W L E					
1252	1261	1270	1279	1288	1297
ACC TGG TTA CAG TGT AGA AAA CAG CTT GGA TTA CTA AGT TTT TTC TTC GCT ATG					
T W L Q C R K <u>Q L G L L S F F F A M</u>					
1306	1315	1324	1333	1342	1351
GTC CAT GTT GCC TAC AGC CTC TGC TTA CCG ATG AGA AGG TCA GAG AGA TAT TTG					
<u>V H V A Y S L C L P M</u> R R S E R Y L					
1360	1369	1378	1387	1396	1405
TTT CTC AAC ATG GCT TAT CAG CAG GTT CAT GCA AAT ATT GAA AAC TCT TGG AAT					
F L N M A Y Q Q V H A N I E N S W N					
1414	1423	1432	1441	1450	1459
GAG GAA GAA GTT TGG AGA ATT GAA ATG TAT ATC TCC TTT GGC ATA ATG AGC CTT					
E E E V W R I E <u>M Y I S F G I M S L</u>					

1468	1477	1486	1495	1504	1513
GGC TTA CTT TCC CTC CTG GCA GTC ACT TCT ATC CCT TCA GTG AGC AAT GCT TTA					
<u>G L L S L L A V T S I P S</u>	<u>V</u>	<u>S</u>	<u>N</u>	<u>A</u>	<u>L</u>
1522	1531	1540	1549	1558	1567
AAC TGG AGA GAA TTC AGT TTT ATT CAG TCT ACA CTT GGA TAT GTC GCT CTG CTC					
<u>N</u>	<u>W</u>	<u>R</u>	<u>E</u>	<u>F</u>	<u>S</u>
<u>F I Q S T L G Y V A L L</u>					
1576	1585	1594	1603	1612	1621
ATA AGT ACT TTC CAT GTT TTA ATT TAT GGA TGG AAA CGA GCT TTT GAG GAA GAG					
<u>I S T F H V L I Y G W</u>	<u>K</u>	<u>R</u>	<u>A</u>	<u>F</u>	<u>E</u>
<u>E</u>	<u>E</u>	<u>E</u>			
1630	1639	1648	1657	1666	1675
TAC TAC AGA TTT TAT ACA CCA CCA AAC TTT GTT CTT GCT CTT GTT TTG CCC TCA					
<u>Y</u>	<u>Y</u>	<u>R</u>	<u>F</u>	<u>Y</u>	<u>T</u>
<u>P P N F V L A L V L P S</u>					
1684	1693	1702	1711	1720	1729
ATT GTA ATT CTG GAT CTT TTG CAG CTT TGC AGA TAC CCA GAC TGA GCT GGA ACT					
<u>I V I L D L L Q L C</u>	<u>R</u>	<u>Y</u>	<u>P</u>	<u>D</u>	<u>*</u>
1738	1747	1756	1765	1774	1783
GGA ATT TGT CTT CCT ATT GAC TCT ACT TCT TTA AAA GCG GCT GCC CAT TAC ATT					
1792	1801	1810	1819	1828	1837
CCT CAG CTG TCC TTG CAG TTA GGT GTA CAT GTG ACT GAG TGT TGG CCA GTG AGA					
1846	1855	1864	1873	1882	1891
TGA AGT CTC CTC AAA GGA AGG CAG CAT GTG TCC TTT TTC ATC CCT TCA TCT TGC					
1900	1909	1918	1927	1936	1945
TGC TGG GAT TGT GGA TAT AAC AGG AGC CCT GGC AGC TGT CTC CAG AGG ATC AAA					
1954	1963	1972	1981	1990	1999
GCC ACA CCC AAA GAG TAA GGC AGA TTA GAG ACC AGA AAG ACC TTG ACT ACT TCC					
2008	2017	2026	2035	2044	2053
CTA CTT CCA CTG CTT TTC CTG CAT TTA AGC CAT TGT AAA TCT GGG TGT GTT ACA					
2062	2071	2080	2089	2098	2107
TGA AGT GAA AAT TAA TTC TTT CTG CCC TTC AGT TCT TTA TCC TGA TAC CAT TTA					
2116	2125	2134	2143	2152	2161
ACA CTG TCT GAA TTA ACT AGA CTG CAA TAA TTC TTT CTT TTG AAA GCT TTT AAA					
2170	2179	2188	2197	2206	2215
GGA TAA TGT GCA ATT CAC ATT AAA ATT GAT TTT CCA TTG TCA ATT AGT TAT ACT					
2224	2233	2242	2251	2260	2269
CAT TTT CCT GCC TTG ATC TTT CAT TAG ATA TTT TGT ATC TGC TTG GAA TAT ATT					
2278	2287	2296	2305	2314	2323
ATC TTC TTT TTA ACT GTG TAA TTG GTA ATT ACT AAA ACT CTG TAA TCT CCA AAA					
2332	2341	2350	2359	2368	2377
TAT TGC TAT CAA ATT ACA CAC CAT GTT TTC TAT CAT TCT CAT AGA TCT GCC TTA					
2386	2395	2404	2413	2422	2431
TAA ACA TTT AAA TAA AAA GTA CTA TTT AAT GAT TTA AAA AAA AAA AAA AAA AAA					
2440	2449				
AAA AAA AAA AAA AAA AAA AA 3'					

## FIG. 10A

1 CGAAACTTCC CTCTACCCGC CCGGCCCGCG GCGCGCACCG TTGGCGCTGG ACGCTTCCTC  
 GCTTTGAAGG GAGATGGGCG GGCCGGGCGC GCGCGTGGC AACCGCGACC TGCGAAGGAG

M E K T C I D A L P L T  
 61 CTTGGAAGCG CCTCTCCCTC **AGTTATGGAG** AAAACTTGTA TAGATGCACT TCCTCTTACT  
 GAACCTTCGC GGAGAGGGAG TCAATACCTC TTTTGAACAT ATCTACGTGA AGGAGAATGA

M N S S E K Q E T V C I F G T G D F G R  
 121 ATGAATTCTT CAGAAAAGCA AGAGACTGTA TGTATTTTTG GAACTGGTGA TTTTGGAGA  
 TACTTAAGAA GTCTTTTCGT TCTCTGACAT ACATAAAAAC CTTGACCACT AAAACCTTCT

S L G L K M L Q C G Y S V V F G S R N P  
 181 TCACTGGGAT TGAAAATGCT CCAGTGTGGT TATTCTGTTG TTTTGGGAAG TCGAAACCCC  
 AGTGACCCTA ACTTTTACGA GGTACACCA ATAAGACAAC AAAACCTTC AGCTTTGGGG

Q K T T L L P S G A E V L S Y S E A A K  
 241 CAGAAGACCA CCCTACTGCC CAGTGGTGA GAAGTCTTGA GCTATTCAGA AGCAGCCAAG  
 GTCTTCTGGT GGGATGACGG GTCACCACGT CTTCAGAACT CGATAAGTCT TCGTCGGTTC

K S G I I I I A I H R E H Y D F L T E L  
 301 AAGTCTGGCA TCATAATCAT AGCAATCCAC AGAGAGCATT ATGATTTTCT CACAGAATTA  
 TTCAGACCGT AGTATTAGTA TCGTTAGGTG TCTCTCGTAA TACTAAAAGA GTGTCTTAAT

T E V L N G K I L V D I S N N L K I N Q  
 361 ACTGAGGTTT TCAATGGAAA AATATTGGTA GACATCAGCA ACAACCTCAA AATCAATCAA  
 TGACTCCAAG AGTTACCTTT TTATAACCAT CTGTAGTCGT TGTGGAGTT TTAGTTAGTT

Y P E S N A E Y L A H L V P G A H V V K  
 421 TATCCAGAAT CTAATGCAGA GTACCTTGCT CATTTGGTGC CAGGAGCCCA CGTGGAATAA  
 ATAGGTCTTA GATTACGTCT CATGGAACGA GTAAACCACG GTCCTCGGGT GCACCATTTT

A F N T I S A W A L Q S G A L D A S R Q  
 481 GCATTTAACA CCATCTCAGC CTGGGCTCTC CAGTCAGGAG CACTGGATGC AAGTCGGCAG  
 CGTAAATTGT GGTAGAGTCG GACCCGAGAG GTCAGTCCTC GTGACCTACG TTCAGCCGTC

V F V C G N D S K A K Q R V M D I V R N  
 541 GTGTTTGTGT GTGGAAATGA CAGCAAAGCC AAGCAAAGAG TGATGGATAT TGTTCGTAAT  
 CACAAACACA CACCTTTACT GTCGTTTCGG TTCGTTTCTC ACTACCTATA ACAAGCATTA

L G L T P M D Q G S L M A A K E I E K Y  
 601 CTTGGACTTA CTCCAATGGA TCAAGGATCA CTCATGGCAG CCAAAGAAAT TGAAAAGTAC  
 GAACCTGAAT GAGGTTACCT AGTTCCTAGT GAGTACCGTC GGTTCCTTTA ACTTTTCATG

P L Q L F P M W R F P F Y L S A V L C V  
 661 CCCCTGCAGC TATTTCGAAT GTGGAGGTTT CCCTTCTATT TGTCTGCTGT GCTGTGTGTC  
 GGGGACGTCG ATAAAGGTTA CACCTCCAAG GGGGAAGATAA ACAGACGACA CGACACACAG

F L F F Y C V I R D V I Y P Y V Y E K K  
 721 TTCTTGTTTT TCTATTGTGT TATAAGAGAC GTAATCTACC CTTATGTTTA TGAAAAGAAA  
 AAGAACAAA AGATAACACA ATATTCTCTG CATTAGATGG GAATACAAAT ACTTTTCTTT

D N T F R M A I S I P N R I F P I T A L  
 781 GATAATACAT TTCGTATGGC TATTTCCATT CCAAATCGTA TCTTTCCAAT AACAGCACTT  
 CTATTATGTA AAGCATACCG ATAAAGGTAA GGTTTAGCAT AGAAAGGTTA TTGTCGTGAA

T L L A L V Y L P G V I A A I L Q L Y R  
 841 ACACTGCTTG CTTTGGTTTA CCTCCCTGGT GTTATTGCTG CCATTCTACA ACTGTACCGA  
 TGTGACGAAC GAAACCAAAT GGAGGGACCA CAATAACGAC GGTAAGATGT TGACATGGCT

G T K Y R R F P D W L D H W M L C R K Q  
 901 GGCACAAAAT ACCGTTCGATT CCCAGACTGG CTTGACCACT GGATGCTTTG CCGAAAGCAG  
 CCGTGTTTTA TGGCAGCTAA GGGTCTGACC GAACTGGTGA CCTACGAAAC GGCTTTTCGTC

L G L V A L G F A F L H V L Y T L V I P  
 961 CTTGGCTTGG TAGCTCTGGG ATTTGCCTTC CTTTATGTCC TCTACACACT TGTGATTCTT  
 GAACCGAACC ATCGAGACCC TAAACGGAAG GAAGTACAGG AGATGTGTGA AACTAAGGA

I R Y Y V R W R L G N L T V T Q A I L K  
 1021 ATTCGATATT ATGTACGATG GAGATTGGGA AACTTAACCG TTACCCAGGC AATACTCAAG  
 TAAGCTATAA TACATGCTAC CTCTAACCCCT TTGAATTGGC AATGGGTCCG TTATGAGTTC

K E N P F S T S S A W L S D S Y V A L G  
 1081 AAGGAGAATC CATTTAGCAC CTCCTCAGCC TGGCTCAGTG ATTCATATGT GGCTTTGGGA  
 TTCTCTTAG GTAAATCGTG GAGGAGTCGG ACCGAGTCAC TAAGTATACA CCGAAACCCCT

I L G F F L F V L L G I T S L P S V S N  
 1141 ATACTTGGGT TTTTCTGTT TGTACTCTTG GGAATCACTT CTTTGCCATC TGTTAGCAAT  
 TATGAACCCA AAAAAGACAA ACATGAGAAC CCTTAGTGAA GAAACGGTAG ACAATCGTTA

A V N W R E F R F V Q S K L G Y L T L I  
 1201 GCAGTCAACT GGAGAGAGTT CCGATTTGTC CAGTCCAAAC TGGGTATTAT GACCCTGATC  
 CGTCAGTTGA CCTCTCTCAA GGCTAAACAG GTCAGGTTTG ACCCAATAAA CTGGGACTAG

L C T A H T L V Y G G K R F L S P S N L  
 1261 TTGTGTACAG CCCACACCCT GGTGTACGGT GGAAGAGAT TCCTCAGCCC TTCAAAATCTC  
 AACACATGTC GGGTGTGGGA CCACATGCCA CCCTTCTCTA AGGAGTCGGG AAGTTTAGAG

R W Y L P A A Y V L G L I I P C T V L V  
 1321 AGATGGTATC TTCCTGCAGC CTACGTGTTA GGGCTTATCA TTCCTTGCAC TGTGCTGGTG  
 TCTACCATAG AAGGACGTCG GATGCACAAT CCCGAATAGT AAGGAACGTG ACACGACCAC

I K F V L I M P C V D N T L T R I R Q G  
 1381 ATCAAGTTTG TCCTAATCAT GCCATGTGTA GACAACACCC TTACAAGGAT CCGCCAGGGC  
 TAGTTCAAAC AGGATTAGTA CCGTACACAT CTGTTGTGGG AATGTTCTTA GGCGGTCCCG

W E R N S K H  
 1441 TGGGAAAGGA ACTCAAAACA CTAGAAAAG CATTGAATGG AAAATCAATA TTTAAACAA  
 ACCCTTTCCT TGAGTTTTGT GATCTTTTTC GTAACCTACC TTTTAGTTAT AAATTTTGT

1501 AGTTCAATTT AGCTGGATTT CTGAACTATG GTTTTGAATG TTAAAGAAG AATGATGGGT  
 TCAAGTTAAA TCGACCTAAA GACTTGATAC CAAACTTAC AAATTTCTTC TTACTACCCA

1561 ACAGTTAGGA AAGTTTTTTT CTTACACCGT GACTGAGGGA AACATTGCTT GTCTTTGAGA  
 TGTCAATCCT TTCAAAAAA GAATGTGGCA CTGACTCCCT TTGTAACGAA CAGAACTCT

1621 AATTGACTGA CATACTGGAA GAGAACACCA TTTTATCTCA GGTTAGTGAA GAATCAGTGC  
 TTAAGTACT GTATGACCTT CTCTTGTGGT AAAATAGAGT CCAATCACTT CTTAGTCACG

1681 AGGTCCCTGA CTCTTATTTT CCCAGAGGCC ATGGAGCTGA GATTGAGACT AGCCTTGTGG  
 TCCAGGGACT GAGAATAAAA GGGTCTCCGG TACCTCGACT CTAACCTCTGA TCGGAACACC  
 1741 TTTCACACTA AAGAGTTTCC TTGTTATGGG CAACATGCAT GACCTAATGT CTTGCAAAAT  
 AAAGTGTGAT TTCTCAAAGG AACAATACCC GTTGTACGTA CTGGATTACA GAACGTTTTA  
 1801 CCAATAGAAG TATTGCAGCT TCCTTCTCTG GCTCAAGGGC TGAGTTAAGT GAAAGGAAAA  
 GGTATCTTC ATAACGTCGA AGGAAGAGAC CGAGTTCCCG ACTCAATCA CTTTCCTTTT  
 1861 ACAGCACAAT GGTGACCACT GATAAAGGCT TTATTAGGTA TATCTGAGGA AGTGGGTCAC  
 TGTCGTGTTA CCACTGGTGA CTATTTCCGA AATAATCCAT ATAGACTCCT TCACCCAGTG  
 1921 ATGAAATGTA AAAAGGGAAT GAGGTTTTTG TTGTTTTTTG GAAGTAAAGG CAAACATAAA  
 TACTTTACAT TTTTCCCTTA CTCCAAAAAC AACAAAAAAC CTTCAATTCC GTTTGTATTT  
 1981 TATTACCATG ATGAATTCTA GTGAAATGAC CCCTTGACTT TGCTTTTCTT AATACAGATA  
 ATAATGGTAC TACTTAAGAT CACTTTACTG GGGAACTGAA ACGAAAAGAA TTATGTCTAT  
 2041 TTTACTGAGA GGAACATTTT TTATAACACA AGAAAAATTT ACAATTGATT AAAAGTATCC  
 AAATGACTCT CCTTGATAAA AATATTGTGT TCTTTTTTAA TGTTAACATA TTTTCATAGG  
 2101 ATGTCTTGGA TACATACGTA TCTATAGAGC TGGCATGTAA TTCTTCCTCT ATAAAGAATA  
 TACAGAACCT ATGTATGCAT AGATATCTCG ACCGTACATT AAGAAGGAGA TATTTCTTAT  
 2161 GGTATAGGAA AGACTGAATA AAAATGGAGG GATATCCCCT TGGATTTTAC TTGCATTGTG  
 CCATATCCTT TCTGACTTAT TTTTACCTCC CTATAGGGGA ACCTAAAGTG AACGTAACAC  
 2221 CAATAAGCAA AGAAGGGTTG ATAAAAGTTC TTGATCAAAA AGTTCAAAGA AACCAGAATT  
 GTTATTCGTT TCTTCCCAAC TATTTTCAAG AACTAGTTTT TCAAGTTTCT TTGGTCTTAA  
 2281 TTAGACAGCA AGCTAAATAA ATATTGTAAA ATTGCACTAT ATTAGGTTAA GTATTATTTA  
 AATCTGTCGT TCGATTTTATT TATAACATTT TAACGTGATA TAATCCAATT CATAATAAAT  
 2341 GGTATTATAA TATGCTTTGT AAATTTTATA TTCCAAATAT TGCTCAATAT TTTTCATCTA  
 CCATAATATT ATACGAAACA TTTAAAATAT AAGGTTTATA ACGAGTTATA AAAAGTAGAT  
 2401 TTAAATTAAT TTCTAGTGTA AATAAGTAGC TTCTATATCT GTCTTAGTCT ATTATAATTG  
 AATTTAATTA AAGATCACAT TTATTCATCG AAGATATAGA CAGAATCAGA TAATATTAAC  
 2461 TAAGGAGTAA AATTAAATGA ATAGTCTGCA GGTATAAATT TGAACAATGC ATAGATGATC  
 ATTCCTCATT TTAATTTACT TATCAGACGT CCATATTTAA ACTTGTTACG TATCTACTAG  
 2521 GAAAATTACG GAAAATCATA GGGCAGAGAG GTGTGAAGAT TCATCATTAT GTGAAATTTG  
 CTTTTAATGC CTTTLAGTAT CCCGTCTCTC CACACTTCTA AGTAGTAATA CACTTTAAAC  
 2581 GATCTTTCTC AAATCCTTGC TGAAATTTAG GATGGTTCTC ACTGTTTTTC TGTGCTGATA  
 CTAGAAAGAG TTTAGGAACG ACTTTAAATC CTACCAAGAG TGACAAAAAG ACACGACTAT  
 2641 GTACCCTTTC CAAGGTGACC TTCAGGGGGA TTAACCTTCC TAGCTCAAGC AATGAGCTAA  
 CATGGGAAAG GTTCCACTGG AAGTCCCCCT AATTGGAAGG ATCGAGTTCT TACTCGATT  
 2701 AAGGAGCCTT ATGCATGATC TTCCACATA TCAAAATAAC TAAAAGGCAC TGAGTTTGGC  
 TTCTCGGAA TACGTACTAG AAGGTGTAT AGTTTTATTG ATTTTCCGTG ACTCAAACCG  
 2761 ATTTTTCTGC CTGCTCTGCT AAGACCTTTT TTTTTTTTTT ACTTTCATTA TAACATATTA  
 TAAAAAGACG GACGAGACGA TTCTGGAAAA AAAAAAAAAA TGAAAGTAAT ATTGATATAAT

2821 TACATGACAT TATACAAAAA TGATTAAAAT ATATTAAAAC AACATCAACA ATCCAGGATA  
 ATGTACTGTA ATATGTTTTT ACTAATTTTA TATAATTTTG TTGTAGTTGT TAGGTCCTAT  
  
 2881 TTTTCTATA AAACTTTTTA AAAATAATTG TATCTATATA TTCAATTTTA CATCCTTTTT  
 AAAAAAGATAT TTTGAAAAAT TTTTATTAAC ATAGATATAT AAGTTAAAAAT GTAGGAAAAA  
  
 2941 CAAAGGCTTT GTTTTTCTAA AGGCTTTGTT TTCCTTTTTTA TTATTTTTTTT CTTTTTTATT  
 GTTCCGAAA CAAAAAGATT TCCGAAACAA AAGGAAAAAT AATAAAAAAA GAAAAAATAA  
  
 3001 TTTTGTAGAC AGTCTTGCTC TGTCGCTCAG GCTGGAGTGC AGTGGCACGA TCTCAGCTCA  
 AAAA ACTCTG TCAGAACGAG ACAGCGAGTC CGACCTCACG TCACCGTGCT AGAGTCGAGT  
  
 3061 CTGCAACCTC CTCCTCCCAG GTTCAAGTGA TTCTTGTTCA TCAGCCTCCC GAGTAGCTGG  
 GACGTTGGAG GAGGAGGGTC CAAGTTCACT AAGAACAAGT AGTCGGAGGG CTCATCGACC  
  
 3121 GACTACAGGC ATGTGCCACT ATGCCAGCT AATTTTTGTA CTTT TAGTAG AGACAGGGTT  
 CTGATGTCCG TACACGGTGA TACGGTCTGA TTAAAAACAT GAAAATCATC TCTGTCCCAA  
  
 3181 TCACCACATT GGT CAGGCTG GTCTTGAAAT GCTGGCGTCA AGTGATCTGC CTGCCTCCGC  
 AGTGGTGTA CCAGTCCGAC CAGAACTTTA CGACCGCAGT TCACTAGACG GACGGAGGCG  
  
 3241 CTTACGTAAT ATATTTTCTT AATGGCTGCA TAATATCACA TCAAATAGGC ATTTTTCAAA  
 GAATGCATTA TATAAAGAA TTACCGACGT ATTATAGTGT AGTTTATCCG TAAAAAGTTT  
  
 3301 CCTCTTTCCT TATTAAACAT GTAGACTATA TCCATTTTTT ACTAAAATAA ATAACATTTC  
 GGAGAAAGGA ATAATTTGTA CATCTGATAT AGGTAAAAAA TGATTTTATT TATTGTAAAG  
  
 3361 AGATAATATC TTTGCACTGA TAATGTTGCC AAGCCATTTT TAAAGTGACC TTATCAATTT  
 TCTATTATAG AAACGTGACT ATTACAACGG TTCGGTAAAG ATTTCACTGG AATAGTTAAA  
  
 3421 AATTACCATT GGATGAGGGT GTTGCTTTCA TCGCACCATT GTAGATTGTC TTTT TATTTT  
 TTAATGGTAA CCTACTCCA CAACGAAAGT AGCGTGGTAA CATCTAACAG AAAAAATAAA  
  
 3481 CAATTTGCGT TTATTTATAA CTGGTTGCAA AGGTACACAG AACACACGCT CCTTCAACTT  
 GTTAAACGCA AATAAATATT GACCAACGTT TCCATGTGTC TTGTGTGCGA GGAAGTTGAA  
  
 3541 ATCTTTGATA AACCCAAGCA AGGATACAAA AAGTTGGACG ACATTGAGTA GAGTCATGGT  
 TAGAACTAT TTGGGTTTCG TCCTATGTTT TTCAACCTGC TGTAACCTCAT CTCAGTACCA  
  
 3601 ATACGGTGCT GACCCTACAG TATCAGTGGA AAAGATAAGG AAAATGTCAC TACTCACCTA  
 TATGCCACGA CTGGGATGTC ATAGTCACCT TTTCTATTCC TTTTACAGTG ATGAGTGGAT  
  
 3661 TGTATGCAA AACAGTTAGG TGTGCTGGGG CTGGATACTG CTCTTTTACT TGAGCATTGG  
 ACAATACGTT TTGTCAATCC ACACGACCCC GACCTATGAC GAGAAAATGA ACTCGTAACC  
  
 3721 TTGATTAAAG TTTAGGTACC ATCCAGGCTG GTCTAGAGAA GTCTTTGGAG TTAACCATGC  
 AACTAATTTT AAATCCATGG TAGGTCCGAC CAGATCTCTT CAGAAACCTC AATTGGTACG  
  
 3781 TCTTTTGTG AAAGAAGAGA GTAATGTGTT TATCCTGGCT CATAGTCCGT CACCGAAAAT  
 AGAAAAACAA TTTCTTCTCT CATTACACAA ATAGGACCGA GTATCAGGCA GTGGCTTTTA  
  
 3841 AGAAAATGCC ATCCATAGGT AAAATGCTGA CCTATAGAAA AAAATGAACT CTACTTTTAT  
 TCTTTTACGG TAGGTATCCA TTTTACGACT GGATATCTTT TTTTACTTGA GATGAAAATA  
  
 3901 AGCCTAGTAA AAATGCTCTA CCTGAGTAGT TAAAAGCAAT TCATGAAGCC TGAAGCTAAA  
 TCGGATCATT TTTACGAGAT GGACTCATCA ATTTTCGTTA AGTACTTCGG ACTTCGATTT

3961 GAGCACTCTG ATGGTTTTGG CATAATAGCT GCATTTCCAG ACCTGACCTT TGGCCCCAAC  
CTCGTGAGAC TACCAAAACC GTATTATCGA CGTAAAGGTC TGGACTGGAA ACCGGGGTTG

4021 CACAAGTGCT CCAAGCCCCA CCAGCTGACC AAAGAAAGCC CAAGTTCTCC TTCTGTCCTT  
GTGTTACGA GGTTCGGGGT GGTCGACTGG TTTCTTTCGG GTTCAAGAGG AAGACAGGAA

4081 CCCACAACCT CCCTGCTCCC AAAACTATGA AATTAATTTG ACCATATTAA CACAGCTGAC  
GGGTGTTGGA GGGACGAGGG TTTTGATACT TTAATTAAAC TGGTATAATT GTGTCGACTG

4141 TCCTCCAGTT TACTTAAGGT AGAAAGAATG AGTTTACAAC AGATGAAAAT AAGTGCTTTG  
AGGAGGTCAA ATGAATTCCA TCTTCTTAC TCAAATGTTG TCTACTTTTA TTCACGAAAC

4201 GGCGAACGTG ATTCCTTTTA ACAGATCCAA ACTATTTTAC ATTTAAAAAA AAAGTTAAAC  
CCGCTTGACA TAAGGAAAAT TGTCTAGGTT TGATAAAATG TAAATTTTTT TTTCAATTG

4261 TAAACTTCTT TACTGCTGAT ATGTTTCCTG TATTCTAGAA AAATTTTTTAC ACTTTCACAT  
ATTTGAAGAA ATGACGACTA TACAAAGGAC ATAAGATCTT TTTAAAAATG TGAAAGTGTA

4321 TATTTTTGTA CACTTCCCC ATGTTAAGGG ATGATGGCTT TTATAAATGT GTATTCATTA  
ATAAAACAT GTGAAAGGGG TACAATTCCC TACTACCGAA AATATTTACA CATAAGTAAT

4381 AATGTTACTT TAAAAATAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA  
TTACAATGAA ATTTTATTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT

## FIG. 10B

STEAP-2, AA508880 (NCI\_CGAP Pr6)

ggtcgacttttctttattcctttgtcagagatctgattcatccatagctagaaaccaacagagtgacttttaca  
aaattcctatagagattgtgaataaaaaccttacctatagttgccattactttgctctccctagtataccttgcagg  
tcttctggcagctgcttatcaactttattacggcaccaagtataggagatttccaccttggttggaacctgggta  
cagtgtagaaaacagcttggtactaagttgtttcttcgctatggtccatggtgcctacagcctctgcttaccga  
tgagaaggtcagagagat

STEAP-2, 98P4B6 SSH fragment

TTTGACGCTTTGCAGATACCCAGACTGAGCTGGAAGTGAATTTGTCTTCCTATTGACTCTACTTCTTTAAAGCG  
GCTGCCATTACATTCCTCAGCTGTCCTTGACGTTAGGTGTACATGTGACTGAGTGTGGCCAGTGAGATGAAGTC  
TCCTCAAAGGAAGGCAGCATGTGTCTTTT

STEAP-3, AI139607 (testis EST)

aagaaggagaatccatttagcacctcctcagcctggctcagtgattcatatgtggctttgggaataacttgggtttt  
ttctgtttgtactcttgggaatcacttctttgccatctgttagcaatgcagtcaactggagagagttccgatttgt  
ccagtcctaaactgggttatttgacctgatcttgtgtacagcccacacctgggtgtacgggtgggaagagattcctc  
agcccttcaaatctcagatgggtatcttctcgcagcctacgtgttagggcttatcattccttgcactgtgctgggtga  
tcaagtttgcctaatcatgccatgtgtagacaacaccttacaaggatccgccagggctgggaagggaactcaaa  
acactagaaaaagcattgaatggaaaatcaatatttaaaacaaagttcaatttagctggaaaaaaaaa

STEAP 4, R80991 (placental EST)

ggccgcggcancgcctacgacctgggtcaacctggcagtcagcaggtcttggccanacaagagccacctctgggtg  
aaggaggaggtctggcggatggagatctacctctccctgggagtgctggccctcggcacgttgcctgctggccg  
tgacctcactgccgtccattgcaaaactcgtcactggaggagttcagcttcggttcagtcctcactgggctttgt  
ggcctcgtgctgagcacactncacacgctcacctacggctggaccgcgccttcgaggagagccgctacaagttc  
tacctncctcccaccttcacgntcacgctgctggtgcctgcgttcggttcacctcctggccaaagccctgttntac  
tgcttgcattcagccgnaga



FIG. 11A

1	15 16	30 31	45 46	60 61	75 76	90	
2 STEAP2	MESISMMSGPKSLSE	TC---	LPNGINGIKD	ARKVTVGVISGDFA	KSNITIRLIRCGYHV	IGSRNEKPASEFFPH	VVDVTHHEDALTKTN
3 STEAP3	-----MEK	TCIDALPLTNSS-	-KQETVCIFGTGDEG	RSGLKMLQCGYSVV	FGSRNEOKTIT-LLPS	GAEVLISYSEAAKKS	---
4 STEAP1	-----	-----	-----	-----	-----	-----	---
5 STEAP4	-----	-----	-----	-----	-----	-----	---
91	105 106	120 121	135 136	150 151	165 166	180	
2 STEAP2	ITFVAIHREHYTSEW	DIRHLVGGKTHIDVS	NNMRINQYPESNARY	LASLFFDLSLIYKGFN	VVSAAWALQGPKDAS	ROYVICSNNIQARQQ	177
3 STEAP3	ITIIIAIHREHYDFHT	EUTEVINGKTHVDIS	NNLKNQYPESNARY	LAHLVPGAHVVKAFN	TISAAWALQSGALDAS	ROYFVGNDSDSAKQR	165
4 STEAP1	-----	-----	-----	-----MESKDIYN	QBELNKKM-PRNLE	EDDYL--HKDTGETS	36
5 STEAP4	-----	-----	-----	-----	-----	-----	0
181	195 196	210 211	225 226	240 241	255 256	270	
2 STEAP2	VIELARQENF-IPID	LGSLSSAREIDENLPH	RLETILNRGCVVVAIS	LATEFFTVSFVRDVI	HPYARNQQSDFYKIP	TEIVNKTLEPIVATITL	266
3 STEAP3	VMDIVRNLCG-TPMD	QGSUMAAKEIEKYPI	QLEPMNRPFPYLSAV	LCVELNPFYCVIRDVI	YPAVYEKKDNTFERMA	ISEPNRIFPILTALPL	254
4 STEAP1	MLKRPVLHHHQTAH	ADEFDCPSELQH-TQ	ELFEPQWHLFIKIAAI	IASLTFENTLLIREVI	HPLATSHQQVETKIP	ILVINKVLEPMVSIETL	125
5 STEAP4	-----	-----	-----	-----	-----	-----	0
271	285 286	300 301	315 316	330 331	345 346	360	
2 STEAP2	LSLVYUAGLLAAAYQ	EYGTGKVRKFPFPMLE	TWLOGRKQIGLSIFF	FAMVHVAYSICLPMR	RSERYLFLFNAYQQV	HANIENSNNNEEEVWR	356
3 STEAP3	LALVYLPGVIAAIPLO	LYRGTKVRKFPFDMLD	HMMEGRKQIGLGVALG	PAFELHVLATLVIPIR	YYVRWELGNLTVTQA	ILKKENPFSTSSAWL	344
4 STEAP1	LALVYLPGVIAAIVQ	LHNGTKVKKKTFPHWLD	KWMLTRKQFGGLISFF	PAVTHAIVSLSYPMR	RSYRKLLNNWAYQQV	QQNKEDAWLEHDVWR	215
5 STEAP4	-----	-----	-----	-----A	AAXAITWTSTWQSRS	WPXKSHLWVKEEVWR	31



[illegible]

```

STRAP-1      167 LFPQWHLPIKIAAIIASLTFLYITLLREVIHPLATSHQQYFYKIPILVINKVLPMSITLL
STRAP-2      208 LFTLWRGFPVVVAISLATFFFLYSFVRDVIHPYARNQQSDFYKIPIEIVNKTLPIVAITLL
              ** * * * * * ** * * * * * * * * * * * * * * *
STRAP-1      127 ALVYLPGVIAAIVQLHNGTKYKKFPHWLDKWMLTRKQFGLLSFFFAVLHAIYSLSYPMRR
STRAP-2      268 SLVYLAGLLAAAYQLYYGTKYRRFPFWLETWLQCRQLGLLSFFFAMVHVAYSCLCPLMR
              **** * * * * * ** * * * * * * * * * * * * * * *
STRAP-1      187 SYRYKLLNWAYQQVQONKEDAWIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLT
STRAP-2      328 SERYLEFLNMAQQVHANIEHSWNBEVWRIEMYISFGIMSLGLLSLLAVTSIPSVSNALN
              * * * * * ** * * * * * * * * * * * * * * * * * *
STRAP-1      247 WREFHYIQSKLGIVSLLLGTHALIFAWNKWIDIKQFVWYTPPTFMIAVFLPIVVLII
STRAP-2      388 WREFSFQSTTLGIVALLISTFHVLIYGWKRAFEEEYRYFTPFPNFVLALVLPISVIL
              ***** * * * * * * * * * * * * * * * *

```

## FIG. 11C

STEAP1 66 ELFPQWHLPIKIAAIIASLTFLYTLTREVIHPLATSHQQYFYKIPILVINKVLPMSITL

STEAP3 195 QLFPMWRFPPFYLSAVLCVFLFFYCVIRDVIYPVYEKKDNTFRMAISIPNRIFPITALTL  
\*\*\* \* \* \* \* \* \* \* \* \*

STEAP1 126 LALVYLPGVIAAIVQLHNGTKYKKFPHWLDKWMLTRKQFGLLSFFFVAVLHAIYSLSPMR

STEAP3 255 LALVYLPGVIAAILQLYRGTKYRRFPDWLDHWMLCRKQLGLVALGFALHVLYTLVIPIR  
\*\*\*\*\* \*\* \*\*\*\*\* \*\* \* \* \* \* \*

STEAP1 186 RSYRYKLLNWAYQQVQQNKEDAWIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSL

STEAP3 315 YYVRWRLGNLTVTQAILKKENPFSTSSAWLSDSYVALGILGFFLVLLGITSLSVSNV  
\* \* \* \* \*

STEAP1 246 TWREFHYIQSKLGIVSLLLGTIHALIFAWNKWIDIKQFVWYTPPTFMIAVFLPIVVLIFK

STEAP3 375 NWREFRFVQSKLGYLTILCTAHTLVYGGKRFLSPSNLRWYLPAAAYVLGLIIPCTVLVIK  
\*\*\*\* \*\*\*\*\* \* \* \* \* \* \* \* \* \*

STEAP1 306 SILFLPCLRKKILKIRHWEDVTK

STEAP3 435 FVLIMPCVDNTLTRIRQGWERNK  
\* \* \* \* \*

# FIG. 11D

STEAP2 29 RKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGSRNPKFASEFFPHVVDVTHHEDALTKTNI

STEAP3 18 KQETVCIFGTGDFGRSLGLKMLQCGYSVVFGSRNPQ-KTTLLPSGAEVLSYSEAAKKSGI  
 \*\* \* \*\*\* \*\* \*\*\* \*\* \*\*\*\*\* \* \* \* \* \*

STEAP2 89 IFVAIHREHYTSLWDLRHLLVGKILIDVSNMNRINQYPESNAEYLASLFPDSLIVKGFNV

STEAP3 77 IIIIAIHREHYDFLTELTEVLNGKILVDISNNLKINQYPESNAEYLAHLVPGAHVVKAFNT  
 \* \*\*\*\*\* \* \* \* \*\*\*\*\* \* \* \*\*\*\*\*

STEAP2 149 VSAWALQLGPKDASRQVYICSNNIQARQQVIELARQLNFIPIIDLGLSSAREIENLPLRL

STEAP3 137 ISAWALQSGALDASRQVFCGNDKAKQRVMDIVRNGLTPMDQGSILMAAKEIEKYPLQL  
 \*\*\*\*\* \* \*\*\*\*\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

STEAP2 209 FTLWRGPVVVAISLATFFFLYSFVRDVIHPYARNQQSDFYKIPIEIVNKTLPIVAITLLS

STEAP3 197 FPMWRFPFYLSAVLCVFLFFYCVIRDVIYPYVYEKKDNTFRMAISIPNRIFPITALTLA  
 \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

STEAP2 269 LVYLAGLLAAAYQLYYGTYRRFPWLETWLQCRKQLGLLSFFFAMVHVAYSLCLPMRRS

STEAP3 257 LVYLPGVIAAILQLYRGTYRRFPDWLDHWMLCRKQLGLVALGFAFLHVLYTLVIPIRYY  
 \*\*\*\* \* \*\* \*\*\*\* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\* \* \* \* \* \*

STEAP2 329 ERYLFLNMAYQQVHANIEWSNNEEEVWRIEMYISFGIMSLGLLSLLAVTSIPSVSNALNW

STEAP3 317 VRWRLGNLTVTQAILKKENPFSTSSAWLSDSYVALGILGFFLFLVLLGITSLPSVSNVNW  
 \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

STEAP2 389 REFSFIQSTLGYVALLISTFHVLIYGWKRAFEEEYYRFYTPPNFVLALVLPISIVIL

STEAP3 377 REFRFVQSKLGYLTLLCTAHTLVYGGKRFLSPSNLRWYLPAAAYVLGLIIPCTVLV  
 \*\*\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*


FIG. 12A

Panel 1.


Heart  
Brain  
Placenta  
Lung  
Liver  
Skeletal Muscle  
Kidney  
Pancreas

Panel 2.

Spleen  
Thymus  
Prostate  
Testes  
Ovary  
Small Intestine  
Colon  
White Blood Cell



# FIG. 12B




**A**

1. Brain
2. Heart
3. Kidney
4. Liver
5. Lung
6. Pancreas
7. Placenta
8. Skeletal Muscle

**B**

1. Colon
2. Ovary
3. Leukocytes
4. Prostate
5. Small Intestine
6. Spleen
7. Testis
8. Thymus

FIG. 13




- A**
1. Brain
  2. Heart
  3. Kidney
  4. Liver
  5. Lung
  6. Pancreas
  7. Placenta
  8. Skeletal Muscle

- B**
1. Colon
  2. Ovary
  3. Leukocytes
  4. Prostate
  5. Small Intestine
  6. Spleen
  7. Testis
  8. Thymus



FIG.14



**A**

1. Brain
2. Prostate
3. LAPC-4 AD
4. LAPC-4 AI
5. LAPC-9 AD
6. HeLa
7. Murine cDNA
8. Neg. control

**B**

1. Colon
2. Ovary
3. Leukocytes
4. Prostate
5. Small Intestine
6. Spleen
7. Testis
8. Thymus

FIG. 15





FIG. 16

FIG. 16



- |               |              |                 |             |
|---------------|--------------|-----------------|-------------|
| 1. prostate   | 20. PANC-1   | 30. BT-20       | 39. A431    |
| 2. LAPC-4 AD  | 21. BxPC-3   | 31. CAMA-1      | 40. HeLa    |
| 3. LAPC-4 AI  | 22. HPAC     | 32. DU4475      | 41. OV-1063 |
| 4. LAPC-9 AD  | 23. Capan-1  | 33. MCF-7       | 42. PA-1    |
| 5. LAPC-9 AI  | 24. LS180    | 34. MDA-MB-435s | 43. SW626   |
| 6. TsuPr1     | 25. SK-CO-1  | 35. NTERA-2     | 44. CAO-V-3 |
| 7. DU145      | 26. CaCo-2   | 36. NCCIT       |             |
| 8. LNCaP      | 27. LoVo     | 37. TERA-1      |             |
| 9. PC-3       | 28. T84      | 38. TERA-2      |             |
| 10. LAPC-4 CL | 29. Colo-205 |                 |             |
| 11. PrEC      |              |                 |             |

FIG. 17





FIG. 18



**FIG. 19**





FIG. 20



### Lanes

- 1) 1kb ladder
- 2) human female genomic
- 3) 12P11 BAC mus
- 4) human female genomic
- 5) 12P11 BAC mus
- 6) 3T3